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1 Foreword 
 
Recent years have seen a fast increase in the analytical capacity to read genetic 
information and in the ability to understand the link between the genetic information and 
the functioning of organisms. This has increased the scientific knowledge in previously 
underexploited fields. One example is the human microbiota and the understanding of 
the vital role that the microbiota plays in the physiological and psychological human 
health status and well-being. Brain degenerative diseases like Alzheimer and Parkinson 
are, for example, now considered to be linked to abnormalities in the functioning of the 
human gut microbiota. 
This understanding may have revolutionary impact on (personal) healthcare but this 
promise has not yet been fully recognized by the general public or the policy community 
and for example today, microbiota-related policy interventions are mostly restricted to 
the marketing and health claims of possible probiotic foods and food supplements. 
As the JRC is holding the responsibility for the knowledge management of health-related 
scientific information for policy, we present and discuss here the most recent information 
available on the vital role of the human gut microbiota and the associated opportunities 
for human health and well-being. 
This report provides the state-of-the-art of scientific progress and details how we are 
only starting to learn its importance for human health, food and chemicals safety, as well 
as for our protection against environmental stressors. We also indicate why and how the 
human gut microbiota is going to have an impact on healthcare, nutrition and well-being 
and how this may change the way we assess the risks of the food, drugs and chemicals 
we are in contact with. 
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2 Executive summary 
 
Starting at birth and throughout its whole life, the human being keeps an intimate 
interaction with its microbial community for protection, as a filter against aggressions 
from the environment, and as a supplier of beneficiary essential molecules. These 
microorganisms are found mostly in the gut, but also in the oral cavity, uterus and 
vagina and they cover very large areas of the human skin. Taken all together, this 
microbial community is called "microbiota". 
The microbiota co-evolves with and plays an important role in the normal functioning of 
its host organism. The benefits are mutual: for example, the microorganisms in the gut 
are supported, survive and grow using the food a person eats and in return play a key 
role in health throughout human life. However, the microbiota is a living entity, which 
means that its composition may vary quickly and that, for example, pathogenic 
microorganisms may eventually exceed the beneficial and innocuous ones, impeding 
well-being and eventually causing disease. 
Currently, the most exciting example of human body – microbiota interactions is the 
immune response system, as it has been demonstrated that perturbing the equilibrium 
between the cells of the human body and the gut microbiota results in disturbances of 
processes related to inflammation, autoimmunity, metabolism and neurodegeneration. 
Even effects on the development and progression of cancer have been reported.  
The ratio between the cells of a human body and the components of its microbiota is 
generally believed to be between 3 and 10, in other words: for every “human cell” the 
body carries 3 to 10 microbial cells. Each cell in the human body has generally the same 
genetic information: for example, a nerve cell differs from a liver cell not in the content 
of its genetic material, but in the way that this genetic information is used. The 
microbiota, in contrast, consists of a large multitude of different genomes that thus 
potentially encode for a multiplicity of characteristics as compared to human body cells. 
Moreover, it is known that bacteria often exchange very large fragments of genetic 
material among them, thus vastly increasing the genetic versatility of the microbiota. 
Irrespective thus of the actual numbers or ratio, it is essential to recognise that 
macroscopically the whole human body is a "super-organism" made up of cells that 
themselves are organised in structures like organs and of which the microbiota is an 
essential, vital component. Some refer to the human body, together with its microbiota, 
as a unity called "holobiont", a term used to describe a set of different species (in this 
case the human plus the microbiota) that form an ecological unit. Others refer to the 
microbiota as an "organ" of its own. This latter definition however is too strict and it 
should be better to consider it as a "meta-organ", composed of an agglomerate of 
different genomes with genes that are differently expressed in different microbial cells, 
and that interact with yet another set of different and differently expressed genes of the 
host genome and varying environmental contexts. 
It must be stressed that, to date, research on the microbiota is very bacteria-centric and 
mainly focused on those present in the gut. Very few studies have looked at the viral 
component (or virome) and bacteriophages, eukaryotes such as protozoa, yeast and 
fungi, or have looked into other body compartments. 
Nevertheless, the results obtained so far provide a strong indication that human gut 
microbiota are influenced by: 
— The host genome and heritability - although they have a limited effect on the 
microbiota diversity.  
— Early development. The gut microbiota is established early in life, even before birth. 
During the first 2-3 years of life there are significant changes as a result of nutrition 
and the overall environment. 
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— Diet. It is one of the key drivers for the differences in gut microbiota between people 
and across geographies and lifestyles. Food largely determines the intake of 
commensal, food-associated microbes and the composition of the diet will favour 
some species and hinder others. Effects of the geographic location can also be linked 
to differences in dietary patterns and lifestyle in a specific area. 
— Diseases and infections. Antibiotic treatment may affect and kill naturally residing 
beneficial bacteria in the gut, changing the population’s profile of the microbiota. 
— Aging. Both the physiological modification of human organs and systems as well as 
changes in lifestyle have effects on the gut microbiota and its interaction with the 
host.  
Furthermore, the gut microbiota may be associated with effects on human health and 
well-being: 
— Eating behaviour (the microbiota-gut-brain axis), including preliminary evidence for 
the role of the gut microbiota in eating patterns, as well as alcohol and substance use 
disorders. 
— Dysbiosis (i.e. imbalances or alterations in microbial composition or activity) is 
implicated in various diseases such as obesity, type 2 diabetes, cancer, mental health 
issues, coeliac disease, asthma, allergies and inflammatory bowel disease. 
— Infection - The microbiota directly protects against infections by acting as a "gate-
keeper", inhibiting unwanted organisms from colonising the human body. It can also 
act indirectly, by modulating the body's immune system response.  
— Therapeutic drugs - The gut microbiota may inactivate therapeutic drugs, rendering 
them less effective. Alternatively, drugs may be "biotransformed" into different active 
derivatives that can have unpredicted toxic effects. The composition of the microbiota 
was also shown to affect vaccine efficacy. 
— Environmental chemicals and pollutants - As for therapeutic drugs, the 
microbiota interacts with external chemicals with different, unpredictable 
consequences (neutralisation or activation of toxic substances, etc.). Conversely, 
exposure to environmental chemicals can induce microbiota alterations that modulate 
adverse health effects. Screening environmental chemicals should thus include 
toxicity end-points for the microbiota. 
Whereas several factors that affect the microbiota as well as several phenomena that are 
associated with certain microbiota profiles have been determined, there is less clarity on 
how humans can use the microbiota to direct or support improvements in health and 
well-being. For example, in the gut microbiota context, possible therapeutic options that 
have been explored include a change of diet, the addition of non-digestible prebiotics, 
probiotics, and synbiotics to food products, as well as the use of antibiotics and faecal 
microbiota transplantation. While some of these treatments have been reported to be 
effective, reviewers in the field have highlighted the need for studies with larger sample 
sizes (to reach an adequate statistical power), homogeneous patient groups, 
standardised treatments, the elimination of confounding factors, the inclusion of 
measurements of biomarkers related to the immune system and intestinal health, to be 
able to compare results and understand the underlying phenomena. 
Commercial applications leveraging the health potential of manipulating the microbiota 
raise concerns about property rights, accessibility of data, patentability of faecal 
microbiota profiles, financial benefits, etc. When performed outside of the regulated 
establishments, there are additional concerns on safety, follow-up, and exaggerated 
expectations. Today, in many areas such as in faecal transplantation, the clinical 
practitioners demand an adequate framework for microbiota-derived clinical therapies 
and applications. 
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Irrespective of the application, it is evident that the human microbiota is going to impact 
on healthcare, nutrition and well-being. As these microbes are the closest environment 
interacting with us, the microbiota is the first and most important barrier and filter 
between the human body and the environment. The food we eat, the air we breathe, the 
drugs we ingest and the environmental pollutants that enter our body come first into 
contact with the microbiota. The growing awareness of this fact and the observation that 
the human body - microbiota equilibrium may change, or that the microbiota may have a 
beneficial or harmful role in the conversion of the metabolites it encounters, may impact 
the future risk assessment of food, chemicals and drugs. Indeed, the core elements of 
risk assessment as established in the eighties (hazard identification, dose-response 
assessment, exposure assessment and risk assessment) have remained relatively 
unchanged and may require revision in the light of the role of the microbiota. Regardless 
of the approaches used to provide data for various risk assessments (e.g. animal 
toxicology studies, in vitro assays and computational approaches, biomarkers 
assessment), none has explicitly considered the human microbiota and thus risk 
assessment in its current approach may mischaracterise the nature of a hazard 
associated with an exposure to the human body and over- or underestimate the risk. 
Moreover, since the composition and functioning of the microbiota is both very specific to 
an individual and variable in time, a new approach of "personalised", "meta-risk 
assessment" may be required for a comprehensive risk-based approach. 
To summarise, the human gut microbiota is not only expected to impact on healthcare, 
nutrition and well-being, but also on the whole risk assessment framework. 
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3 Abbreviations 
ADME Absorption, distribution, metabolism, and excretion 
ALD Alcoholic liver disease 
CCK Cholecystokinin 
CD Crohn’s disease 
CRC Colorectal cancer 
CVD Cardiovascular disease 
DCA Deoxycholic acid 
DNA Deoxyribonucleic acid 
EFSA European Food Safety Authority 
FDA Food and Drug Administration (USA) 
FGF Fibroblast growth factor 
FIAF Fasting-induced adipocyte factor 
FISH Fluorescent in situ hybridisation 
FOS Fructo-oligosaccharide 
FTIR Fourier transform infrared spectroscopy 
FXR Farnesoid X receptor 
GALT Gut-associated lymphoid tissue 
GC Gas chromatography 
GIP Glucose-dependent insulinotropic polypeptide 
GLP Glucagon-like peptide 
GOS Galacto-oligosaccharide 
GPBAR1 G protein-coupled bile acid receptor 1 
GPCR G protein-coupled receptor 
HBV Hepatitis B virus 
HCC Hepatocellular carcinoma 
HCV Hepatitis C virus 
HDAC Histone deacetylase 
HDL High-density lipoprotein 
IBD Inflammatory bowel disease 
IBS Irritable bowel syndrome 
IND Investigational new drug (USA) 
LC Liquid chromatography 
LCFA Long-chain fatty acid 
LDL Low-density lipoprotein 
LPL Lipoprotein lipase 
LPS Lipopolysaccharides 
MALDI-MSI Matrix-assisted laser desorption/ionisation mass spectrometry imaging 
MCFA Medium-chain fatty acid 
mRNA Messenger RNA 
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MS Mass spectrometry 
NAFLD Non-alcoholic fatty liver disease 
NASH Non-alcoholic steatohepatitis 
NMR Nuclear magnetic resonance 
NSP Non-starch polysaccharides 
OA Osteoarthritis 
PCR Polymerase chain reaction 
PsA Psoriatic arthritis 
PYY Peptide YY, peptide tyrosine tyrosine 
qPCR Quantitative polymerase chain reaction 
QPS Qualified presumption of safety 
RA Rheumatoid arthritis 
RNA Ribonucleic acid 
rRNA Ribosomal RNA 
SCFA Short chain fatty acid 
SIBO Small intestinal bacterial overgrowth 
TMA Trimethylamine 
TMAO Trimethylamine-N-oxide 
TLR Toll-like receptor 
Treg Regulatory T cells  
UC Ulcerative colitis 
UV/Vis Ultraviolet/visible spectroscopy  
VLDL Very low‑density lipoprotein 
XOS Xyloseoligosaccharide 
 7 
4 What is the gut microbiome? 
 
The microbiome can be defined as the community of 
commensal, symbiotic, and pathogenic micro-
organisms that inhabit all kinds of multicellular 
organisms. The term can be used synonymously with 
microbiota or microflora. The term “microbiome” is 
also used to describe the collection of genes that are 
found in those microbial communities. The human 
microbiome can be considered a counterpart to the human genome. 
The human microbiome has co-evolved with the human being as a unity called holobiont 
or hologenome (Salvucci, 2016) (Figure 1). The holobiont is a term used to describe an 
individual host and its microbial community, including viruses and cellular 
microorganisms. It distinguishes itself by not only recognizing hosts and their obligate 
symbionts but also emphasizing the diversity of facultative symbionts and their dynamic 
associations within a host. 
 
 
Figure 1. Holobionts are entities comprised of the host and all of its symbiotic microbes, including 
those which affect the holobiont’s phenotype and have coevolved with the host (blue), those which 
affect the holobiont’s phenotype but have not coevolved with the host (red), and those which do 
not affect the holobiont’s phenotype at all (grey). Microbes in the environment are not part of the 
holobiont (white). 
(© Theis/ASM mSystems, source: Theis et al., 2016) 
In the human microbiome, one can make a distinction between the skin, mouth, nose, 
digestive tract and vagina microbiomes. This study is focussed in the human gut 
microbiome. 
Microorganisms are found throughout the length of the human gastrointestinal tract from 
the mouth to the rectum. The density and composition vary according to anatomical site 
and various impacting factors as will be explained further on. Due to the low pH the 
abundance in the stomach is low. In the large intestine conditions are favourable for a 
dense microbial community. Most of the microorganisms are anaerobic organisms.  
The community of commensal, 
symbiotic, and pathogenic 
microorganisms that inhabit all 
kinds of multicellular 
organisms. 
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The microbiota includes bacteria, fungi, protozoa and viruses. The human gut microbiota 
is estimated to encompass 1013 to 1014 resident microorganisms. This number is often 
quoted as 10 times higher than the number of human body cells, however, more recently 
the ratio is set to be closer to 1:1 (Sender et al., 2016).  
The human microbiota is composed primarily of bacteria from either phylum 
Bacteroidetes (mostly Bacteroides or Prevotella species), that are gram negative, or 
Firmicutes (mostly Clostridium and Lactobacillus species), that are gram positive 
(Consortium, 2012). The majority are strict anaerobes (97 %), mostly belonging to the 
phyla Firmicutes (64 %), Bacteroidetes (23 %), Proteobacteria (8 %), and Actinobacteria 
(3 %); low numbers of the phyla Fusobacteria, Verrucomicrobia, and TM7 (2 %) are also 
present. Fungi and archaea comprise less than 1 % of the total gut microbiota (Cardinelli 
et al., 2015). 
The Bacteroidetes use a very wide range of substrates and are major producers of 
propionate. Among the Firmicutes are species that produce butyrate and that are 
specialist degraders of indigestible polysaccharides. Actinobacteria (that include 
Bifidobacterium spp.), Proteobacteria (including Escherichia coli), and Verrucomicrobia 
(including Akkermansia mucinophila) are typically present in smaller numbers in the 
healthy gut microbiota. Gut microbiota differ in composition between individuals and 
within individuals with age and development (Consortium, 2012; Yatsunenko et al., 
2012). More than 1000 species are identified, while a person on average carries 160 
species (Simpson and Campbell, 2015). The anaerobic bacteria exceed by two or three 
orders of magnitude the facultative anaerobic and aerobic bacteria. Certain bacteria tend 
to be adherent to the mucosal surface, while others are predominant in the lumen. The 
establishment of the human gut microbiota starts early in life before birth. 
The gut microbiota has co-evolved with the host. The gut microbiota plays an important 
role in the normal functioning of the host organism. The benefits are mutual: the 
microorganisms are supported by the food humans eat and play a key role in health 
throughout human life. Next to digestion they are involved in establishing the immune 
system, the defence against pathogens, the endocrine system and mental health. 
Disruption of the normal equilibrium may induce metabolic and brain related disease. 
Most microorganisms reside in the distal part of the human gut (colon). As they play a 
role in the digestion of residual substrates, they contribute to their host in the synthesis 
of vitamins (vitamins K and B12, thiamine, and riboflavin and folate) and essential amino 
acids. Fermentation products of dietary fibres and carbohydrates such as butyrate, 
propionate, and acetate (short-chain fatty acids, SCFAs) act as a major energy source for 
intestinal epithelial cells and may therefore strengthen the mucosal barrier (Simpson and 
Campbell, 2015; Singh et al., 2017). Other metabolites include secondary bile acids 
converted from primary bile acids; metabolites generated from meat-derived choline and 
L-carnitine; and other lipids including conjugated fatty acids and cholesterol (Abdollahi-
Roodsaz et al., 2016). Inflammatory bowel disease, obesity, type 2 diabetes, 
cardiovascular disease, and cancer are correlated with changes in the composition of the 
gut microbiota.  
The emergence of techniques such as pyrosequencing of 16S rRNA, quantitative 
polymerase chain reaction (qPCR) and fluorescent in situ hybridisation (FISH) have 
helped a great deal in studying mechanisms of the symbiotic relationship between host 
and microbiota. The ability to identify and quantify bacterial genera in the gut in studies 
deliberately altering a certain component makes it possible to go from correlation to 
causation. 
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5 Techniques for the study of the microbiome 
 
Thriving in the human gut, a large portion of the microbiota is difficult -or even likely 
impossible- to isolate, identify and culture, providing significant bias to any of the results 
and conclusions obtained with this approach. 
More recent techniques, such as pyrosequencing of 16S rRNA, quantitative polymerase 
chain reaction, fluorescent in situ hybridisation and genomics have overcome these 
difficulties but have each their own advantages and limitations. 
Given the variation of the microbiome -even in the different parts of the gut of one 
individual- data gathering must be rigorously standardised in order to allow comparison. 
Given the technical challenges, it is uncertain if the species that are identified so far can 
serve as a marker function (i.e. they represent a typical broader group of organisms 
reacting in the same way) or if they should be seen as independent species with no 
correlation in their abundance or reaction/influence on certain factors. 
An alternative approach, which is less concerned with the actual species, may be to look 
at metabolic functions and characterise the microbiome in function of its activity. 
5.1 Sampling 
Fresh faecal samples are often used as they are relatively easy to obtain. The method is 
non-invasive and can be carried out privately by study participants (Fu et al., 2016). 
However, bacteria residing in the lumen of the intestine that end up in the stool are 
different from the ones residing in the mucosa. Mucosa-associated bacteria might be 
more important, in which case mucosal biopsy samples are required (Leung et al., 2016). 
Microbial populations also differ depending on the location along the gastrointestinal 
tract. Also, in stool samples variation, both longitudinally and radially, might exist. On 
top of that, day-to-day rhythms may interfere. 
5.2 Detection/identification 
5.2.1 Culture-based methods 
Combinations of plating techniques and staining techniques, i.e., Gram, based on 
physiological and biochemical properties, were the first methods to describe the human 
microbiota (Hiergeist et al., 2015). The biggest disadvantage is that only species that 
survive this laboratory setting are identified. Bacterial culture misses around 80% of the 
bacteria detectable with next generation pyrosequencing (Marrs and Flohr, 2016). Slow-
growing or stressed species are outcompeted by fast-growing species. Inappropriate 
conditions regarding pH, redox state, temperature, or absence of essential nutrient 
molecules may hinder others. Interdependency is another cause of failure.  
However, further developments in high-throughput culture-based methods made it 
possible to increasingly identify more species (microbial culturomics). Still species are 
identified that do not appear in 16S rDNA-targeted approach, possibly because of an 
inefficient DNA extraction protocol (Hiergeist et al., 2015). As such, culture-based 
approaches may complement other methods. 
5.2.2 DNA-based methods 
Fluorescent in situ hybridisation (FISH) probes extracted DNA of a microbial community 
are used to study certain genes of interest (Hiergeist et al., 2015). Also, polymerase 
chain reaction (PCR) is used to amplify genes of interest, clone them in E. coli and 
subsequently sequence them. Sequencing itself has gone through an evolution from the 
slow and costly Sanger method to next-generation sequencing and third-generation 
sequencing (Daliri et al., 2017). 
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16S ribosomal RNA (rRNA) sequencing technique is based on the fact that the 16S rRNA 
gene is highly conserved between taxa of bacteria and archaea. This gene has highly 
conserved and hypervariable sequences (regions V1 to V9). Universal PCR primers can be 
used to match the conserved sections and the variable sequences are used to classify 
bacterial taxa. The method starts with the extraction of genomic DNA, the construction of 
appropriate sequencing libraries, then next-generation sequencing, followed by 
bioinformatic analysis including quality control, and finally the comparison to reference 
databases. The accuracy of the analysis and covered taxa depend on the choice of the 
primers, which may introduce bias. Comparison of results requires amplification of the 
same region. Also, dormant, dead and quiescent bacteria are picked-up. The bacterial 
diversity that this technique can study is limited.  
Whole metagenome shotgun sequencing (WMS) comprises the whole genetic diversity 
including all kingdoms (also viral, fungal, and protozoan organisms). It has a much better 
resolution of bacteria at the species level and allows for annotation of bacterial gene 
clusters and pathways based on direct sequencing of bacterial genes (Kurilshikov et al., 
2017). This technique may be used to define the functional capacity of the microbiome 
(Fu et al., 2016). Knowledge of the bacterial genes allows for a better understanding of 
their roles in human health (Singh et al., 2017). Metagenomics follows the same steps of 
analysis but it’s costlier and more time consuming than 16S rRNA sequencing. Moreover, 
it depends on the availability of reference genome databases (inability to analyse 
genomes absent in the reference databases or genes with unrecognised function). 
Contamination by host DNA is another challenge when biopsy or mucosal material is 
being collected. 
Both methods, PCR based and WMS, may have difficulties in detecting low-abundant 
organisms (Hiergeist et al., 2015). The isolation of highly purified DNA from a wide 
variety of specimens is a challenge and may introduce bias. Contamination in the PCR 
procedure is another burden. Comparing research results is only possible applying 
standardised and quality controlled methods for collecting and sampling (including the 
time of collection), transport, preservation, pre-analytical manipulations, and DNA-
extraction (Fu et al., 2016). 
Sequence-based analyses provide no information on the absolute abundance of bacterial 
cells in a gut sample (Flint et al., 2017). Absolute numbers are estimated most 
accurately by techniques such as fluorescent in situ hybridisation.  
Identifying taxa may not tell the whole story. Often different taxa perform the same 
function. Differences in found taxa between individuals may nevertheless have the same 
outcome in metabolic functions (Betrapally et al., 2016). Betrapally et al. describe 
analysis strategies to cope with this. 
5.2.3 Other techniques 
Metatranscriptomics, sequencing microbial rRNA or messenger RNA (mRNA), can be used 
to gain insight into gene expression patterns (Simpson and Campbell, 2015). Instability 
of the mRNA and the lack of reference data are a problem. Moreover, the analysis gives a 
transient picture of the microbial community.  
Metabolomics and metaproteomics are also being developed. They result in dynamic 
metabolic or protein profiles of the microbiota. Extracting total protein may be 
challenging due to interfering compounds and membrane/matrix-bound proteins. Liquid 
chromatography (LC), gas chromatography (GC), mass spectrometry (MS), LC-MS, GC-
MS, ultraviolet/visible spectroscopy (UV/Vis), Fourier transform infrared spectroscopy 
(FT-IR), Matrix-assisted laser desorption/ionisation mass spectrometry imaging (MALDI-
MSI) and nuclear magnetic resonance (NMR) spectroscopy allow sensitive identification of 
microbial and host cell metabolites (Daliri et al., 2017). The metabolome is influenced by 
a lot of factors and therefore it might be difficult to compare between individuals and 
treatments. Furthermore, it may be difficult to differentiate between host and microbial 
metabolite profiles.  
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6 Effects of/on nutrition 
 
The diet is regarded as one of the key drivers for the differences in gut microbiota 
between people and across geographies and lifestyles. 
As microorganisms are specialised in fermenting certain substrates, even some which are 
indigestible for human enzymes, the composition of the diet will favour some species and 
strains and hinder others. 
Whole diets as well as food components (protein, fat, carbohydrates, polyphenols), 
influence the total bacteria count as well as the relative abundance of certain species. 
Food processing and preservation reduces the intake of commensal, food-associated 
microbes, whereas fermented foods enrich specific bacteria that transiently colonise the 
gut. 
Prebiotics ("a selectively fermented ingredient that allows specific changes, both in the 
composition and/or activity in the gastrointestinal microflora that confers benefits upon 
host well-being and health”) induce enhancement in gut mucosal barrier integrity and 
function, increased host mucosal immunity, increased SCFA production and an associated 
reduction in mucosal interaction of opportunistic enteric pathogens. 
Probiotic effects are very strain specific and cannot be generalised. The probiotics can be 
ingested as such or as part of fermented foods. Since most probiotics do not colonise the 
host’s gut, continuous consumption often is necessary to achieve lasting effects. 
Gut microbiota affects the host in his eating behaviour (the microbiota-gut-brain axis). 
There is preliminary evidence for the role of the gut microbiota in eating and alcohol and 
substance use disorders. 
The diet is regarded as one of the key drivers for the differences in gut microbiota 
between people and across geographies and lifestyles (De Filippo et al., 2010; Graf et al., 
2015; Yatsunenko et al., 2012). Food components, which are indigestible for human 
enzymes, provide substrates for the intestinal microbial metabolism. As microorganisms 
are specialised in fermenting certain substrates, the composition of the diet will favour 
some species and strains and hinder others. To demonstrate the cause effect relation 
between diet and microbiome composition, studies have been undertaken where the diet 
has deliberately been changed (Flint et al., 2017; Graf et al., 2015).  
6.1 Metabolic capacity 
The gut microbiota is responsible for substrate breakdown, production of vitamins, 
signalling molecules and anti-microbial compounds, etc. (Daliri et al., 2017). They 
transform complex indigestible molecules such as dietary fibres and mucin into short 
chain fatty acids (SCFAs).  
The main SCFAs are acetate, propionate and butyrate. They have an important 
physiological function. The highest levels of SCFA are found in the cecum and proximal 
colon, declining toward the distal colon (Koh et al., 2016). Most butyrate is used as 
energy source by the colonic epithelial cells. Butyrate induces the differentiation of 
regulatory T (Treg) cells. Propionate is absorbed and metabolised in the liver. Hepatocyte 
cells use propionate for gluconeogenesis. Acetate can cross the blood-brain barrier and 
reduce appetite via a central homeostatic mechanism. Acetate stimulates the colonic 
epithelium to improve epithelial integrity. Propionate and butyrate affect peripheral 
organs indirectly by activation of hormonal and nervous systems. SCFAs decrease colonic 
pH, decrease circulating cholesterol, inhibit the growth of pathogens, stimulate water and 
sodium absorption, provide energy to the colonic epithelial cells, and prevent high-fat 
diet induced obesity by stimulating fat oxidation (Daliri et al., 2017).  
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Bacterial species responsible for these products are listed in  
Table 1. Changes in the composition of the microbiota induces changes in metabolites 
that affect the hosts' physiology and disease. SCFAs act via two principal mechanisms: 
by signalling through G protein-coupled receptors (GPCRs), and by inhibiting histone 
deacetylases. 
The metabolic activities of gut microbiota as a whole are influenced by diet and diet-
driven changes in microbiota composition. To understand and explain the shifts in 
metabolite composition it is necessary to identify substrate degrading enzymes in 
species, to confirm that the degraded products can be utilised, and to demonstrate that 
the specific species can compete with others in the intestines (Flint et al., 2017). In vitro 
fermentation experiments supplying either inulin or pectin as non-digestible carbohydrate 
have demonstrated a specific stimulation of several Bacteroides species (Chung et al., 
2016). 
Table 1. Short Chain Fatty Acids (SCFAs) Production by microbes in the gut. 
(© Koh / Elsevier, Source: Koh et al., 2016) 
SCFAs  Pathways/Reactions Producers 
Acetate from pyruvate via 
acetyl-CoA 
most of the enteric bacteria, e.g., Akkermansia 
mucinophila, Bacteroides spp., Bifidobacterium spp., 
Prevotella spp., Ruminococcus spp. 
Wood-Ljungdahl 
pathway 
Blautia hydrogenotrophica, Clostridium spp., 
Streptococcus spp. 
Propionate succinate pathway Bacteroides spp., Phascolarctobacterium 
succinatutens, Dialister spp., Veillonella spp. 
acrylate pathway Megasphaera elsdenii, Coprococcus catus 
propanediol pathway Salmonella spp., Roseburia inulinivorans, 
Ruminococcus obeum 
Butyrate phosphotransbutyrylas
e/ butyrate kinase 
route 
Coprococcus comes, Coprococcus eutactus 
butyryl-CoA:acetate 
CoAtransferase route 
Anaerostipes spp. (A, L), Coprococcus catus (A), 
Eubacterium rectale (A), Eubacterium hallii (A, L), 
Faecalibacterium prausnitzii (A), Roseburia spp. (A) 
6.2 Whole diets 
Walker and colleagues studied the microbiome of obese volunteers over time receiving 
subsequently a different diet (Walker et al., 2011). Targeted qPCR revealed that, 
although the composition was clearly individual specific, samples showed 
abundance/peaks in specific bacterial groups occurring rapidly after a dietary change. 
The diets only differed in the non-digestible carbohydrate type. The type of non-
digestible carbohydrate substrates is also responsible for a low or high microbiome 
diversity. The low diversity microbiomes tended to be dominated by Bacteroides. Wu et 
al. investigated the influence of a short-term intervention on different long-term diets 
(Wu et al., 2011). Long-term diet low in fat and high in dietary fibre was associated with 
higher Firmicutes, but diet high in fat was more highly associated with Actinobacteria and 
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Bacteroides. The intervention changed the microbiota composition within 24 hours, but 
the magnitude of the effect did not overcome inter-subject variations in the intestinal 
microbiota.  
More drastic shifts were noted when a diet based on animal-derived food versus plant-
based food was compared (David et al., 2014b). Here too, the change in microbiome 
composition was seen within days. The animal-based diet increased the abundance of 
bile-tolerant microorganisms (Alistipes, Bilophila and Bacteroides) and decreased the 
levels of Firmicutes that metabolise dietary plant polysaccharides (Roseburia spp., 
Eubacterium rectale and Ruminococcus bromii). This is consistent with observations that 
high fat intake causes secretion of more bile acids. The same group made a time series 
for two persons (David et al., 2014a). They showed that overall microbial communities 
are stable for months, but sudden changes may alter them. One person travelled from 
the USA to a developing country and was exposed to a novel diet and environment. The 
analysis of stools showed that the Bacteroidetes to Firmicutes ratio increased from 0.37 
(pre-travel) to 0.71 (mid-travel).  
De Filippis and colleagues examined the effect of Mediterranean diet that is characterised 
by a high-level consumption of cereals, fruit, vegetables and legumes (De Filippis et al., 
2016). A significant association was detected between consumption of vegetable-based 
diets and increased levels of faecal SCFAs, Prevotella and some fibre-degrading 
Firmicutes. Several studies investigated the influence of whole grain breakfast cereals or 
flakes on gut microbiota composition. The proportion of Bifidobacterium spp. and the 
Lactobacillus/Enterococcus group was increased compared to the control (Graf et al., 
2015). The influence of fruit consumption, especially berries, is characterised by an 
increase in Bifidobacterium spp. The daily consumption of red wine polyphenol for 4 
weeks significantly increased the number of Enterococcus, Prevotella, Bacteroides, 
Bifidobacterium, Bacteroides uniformis, Eggerthella lenta, and Blautia coccoides-
Eubacterium rectale groups (Queipo-Ortuno et al., 2012).The consumption of chickpeas 
containing significant levels of oligosaccharides had no effect on the taxonomic 
composition or diversity of gut microbiota (Fernando et al., 2010). There was also no 
effect on SCFA concentrations. A study with overweight and obese men drinking soy milk 
showed a decrease in Firmicutes to Bacteroidetes compared to baseline values 
(Fernandez-Raudales et al., 2012). On the influence of nuts, the consumption of 
pistachios had a stronger impact on microbiota composition than the consumption of 
almonds with a higher production of butyrate (Ukhanova et al., 2014).  
A high-protein and moderate-carbohydrate diet was compared with a high-protein and 
low-carbohydrate diet in obese men (Russell et al., 2011). Both diets resulted in 
increased proportions of branched-chain fatty acids and concentrations of phenylacetic 
acid and N-nitroso compounds compared to control diet. Roseburia/Eubacterium rectale 
group of bacteria were reduced resulting in a decrease of the proportion of butyrate in 
faecal SCFA concentrations. Another study with overweight and obese volunteers 
examined the effect of an 8 - week energy-restricted diet of low-carbohydrate, high fat 
compared to a high-carbohydrate, low fat diet (Brinkworth et al., 2009). In the low-
carbohydrate diet, the amount of bifidobacteria dropped and the SCFA levels were lower 
compared to the starting point. Other studies confirmed that with a reduction in dietary 
carbohydrate intake, the abundance of Roseburia spp., Eubacterium rectale and 
Bifidobacterium spp. decrease, and total SCFA reduced in response to this (Simpson and 
Campbell, 2015).  
6.3 Processed food 
Food processing also has an effect on the intestinal microbiota (Graf et al., 2015). Raw 
food, vegetables and fruit, have their own microbiota that is affected by the processing 
method. Highly processed and preserved foods reduce the intake of commensal, food-
associated microbes. Fermented foods like cheese are enriched in lactic acid bacteria that 
transiently colonise the gut (David et al., 2014b).  
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6.4 Single components 
Singh and colleagues performed a systematic literature review on the influence of diet on 
gut microbiota and human health (Singh et al., 2017). They discussed the effect of the 
main food components. 
6.4.1 Protein 
Protein consumption positively correlates with overall microbial diversity. 
Consumption of whey and pea protein extract has been reported to increase gut-
commensal Bifidobacterium and Lactobacillus, while whey additionally decreases the 
pathogenic Bacteroides fragilis and Clostridium perfringens. Pea proteins lead to an 
increase in intestinal SCFA levels. Consuming more animal protein enriches Bacteroides 
and Alistipes in the microbiota and reduces faecal SCFAs. Bifidobacterium spp., 
Lactobacillus spp., Roseburia spp., Eubacterium spp. and Faecalibacterium prausnitzii are 
associated with the increased production of SCFA that are considered anti-inflammatory 
and important for maintenance of the mucosal barrier.  
 
Figure 2. Impact of dietary protein on intestinal microbiota and health outcomes. SCFA (short chain 
fatty acids), TMAO (trimethylamine N-oxide), Tregs (T regulatory cells), CVD (cardiovascular 
disease); IBD (inflammatory bowel disease). 
(© Singh/BMC, source: Singh et al., 2017) 
Red meat consumption is associated with increased levels of trimethylamine-N-oxide 
(TMAO), a proatherogenic compound that increases risk of cardiovascular disease. 
However, an animal protein-based diet usually also means a higher fat intake. It still 
needs to be investigated what influence each constituent has. 
6.4.2 Fat 
Human studies indicate increases in total anaerobic microflora and amount of Bacteroides 
in a high-fat diet. Rats feeding on high-fat feed show less Lactobacillus intestinalis and 
disproportionately more propionate and acetate producing species, including 
Clostridiales, Bacteroides, and Enterobacteriales. A low-fat diet increases human faecal 
abundance of Bifidobacterium at the same time reducing fasting glucose and total 
cholesterol. A high saturated fat diet shows a relative higher proportion of 
Faecalibacterium prausnitzii. No shifts in the relative abundance of any bacterial genera 
is seen with high monounsaturated fat consumption, as in salmon which is high in mono 
and polyunsaturated fats. Lard-fed mice proved to have more Bacteroides and Bilophila, 
while fish-oil-fed mice revealed to have more Actinobacteria (Bifidobacterium and 
Adlercreutzia), lactic acid bacteria (Lactobacillus and Streptococcus), and 
Verrucomicrobia (Akkermansia muciniphila). A saturated lipid diet promotes local 
intestinal immunity through its effects on toll-like receptor (TLR) expression. 
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Figure 3. Impact of dietary fats on intestinal microbiota and host metabolism. TLR: toll-like 
receptor, WAT: white adipose tissue, LDL: low-density lipoprotein 
(© Singh/BMC, source: Singh et al., 2017) 
6.4.3 Carbohydrates 
A distinction is made between digestible carbohydrates (starch, sugars) and 
non‑digestible carbohydrates (fibre). Digestible carbohydrates are enzymatically 
degraded in the small intestine, while non-digestible carbohydrates are fermented in the 
large intestine by microorganisms. Sugars like glucose, lactose, fructose and sucrose 
increase the relative abundance of Bifidobacteria, and reduce the number of Bacteroides. 
Lactose is also decreasing Clostridium species. The opposite effect is seen in a mouse 
study that used artificial sweetener saccharin. This suggests that artificial sweeteners 
may actually be unhealthier to consume than natural sugars.  
Non-digestible carbohydrates when not sufficiently present in the diet reduce total 
bacterial abundance. Addition of non-digestible carbohydrate as in whole grain and wheat 
bran induces an increase in gut Bifidobacteria and Lactobacilli. Resistant starch and 
whole grain barley, appear to also increase abundance of Ruminococcus, Eubacterium 
rectale, and Roseburia. Fructooligosaccharides, polydextrose and arabino-
oligosaccharides are shown to reduce Clostridium and Enterococcus species. The property 
of these fibres to induce shifts in the microbiome provides their additional designation as 
prebiotics. Prebiotics also induce shifts in immune markers: reductions in the pro-
inflammatory cytokine IL-6 and anti-inflammatory cytokine IL-10. Also, metabolites 
change: reduction in serum triglycerides, total cholesterol, low-density lipoprotein (LDL)-
cholesterol, and haemoglobin A1c. 
6.4.4 Polyphenols 
Polyphenols are found in fruits, seeds, vegetables, tea, cocoa products, and wine. 
Consumption of these foods increases Bifidobacterium and Lactobacillus, and for wine in 
particular, relative abundance of Bacteroides is observed, and reduction of the numbers 
of Clostridium perfringens and Clostridium histolyticum. Fruit polyphenols work against 
the enteropathogens Staphylococcus aureus and Salmonella typhimurium. Cocoa-derived 
polyphenols significantly increase plasma high-density lipoproteins and significantly 
reduce plasma triacylglycerol and C-reactive protein concentrations.  
Singh et al. also investigated the impact of Western, gluten-free, omnivore, vegetarian, 
vegan, and Mediterranean diets (Singh et al., 2017).  
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Figure 4. Impact of popular diets on intestinal microbiota and cardiometabolic disease. CVD 
cardiovascular disease, DM2 type 2 diabetes mellitus 
(© Singh/BMC, source: Singh et al., 2017) 
Studies reveal that Western diet (high in animal protein and fat, low in fibre) leads to a 
marked decrease in total bacteria counts and beneficial Bifidobacterium spp. and 
Eubacterium spp. Gluten-free diets allow for the proliferation of E. coli and total 
Enterobacteriaceae, which may include further opportunistic pathogens, and 
Victivallaceae and Clostridiaceae. Furthermore, it decreases the number of beneficial 
Bifidobacterium, Lactobacillus, Ruminococcus bromii and Roseburia faecis. For vegan and 
vegetarian diets study results are not consistent due to differences in methods of 
analysis, reference diets and host genetics. In reviewing studies that compared 
vegetarians to omnivores. Graf et al. came to the same conclusion (Graf et al., 2015). 
Apart from the study by De Filippis et al. mentioned above, other studies described the 
impact of Mediterranean diet as improving obesity, the lipid profile, and inflammation. 
Diet-derived increases in Lactobacillus, Bifidobacterium, and Prevotella, and decreases in 
Clostridium may be the cause. 
6.5 Prebiotics 
A prebiotic is "a selectively fermented 
ingredient that allows specific changes, 
both in the composition and/or activity in 
the gastrointestinal microflora that 
confers benefits upon host well-being and 
health" (de Vrese and Schrezenmeir, 
2008). Food delivering prebiotics are 
soybean, chicory roots, raw oats, 
unrefined wheat, unrefined barley etc. Dietary fibre includes carbohydrates such as 
cellulose, lignin, and non-starch polysaccharides (NSP) such as hemicelluloses. Prebiotic 
oligosaccharides comprise fructo-oligosaccharide (FOS), galacto-oligosaccharides (GOS) 
and xyloseoligosaccharide (XOS) inulin and pectin. They are not digested in the small 
intestine but are fermented in the large intestine by anaerobic colonic microbiota to 
SCFAs. 
Prebiotics confer benefits to the host including enhancement in gut mucosal barrier 
integrity and function, increased host mucosal immunity, increased SCFA production and 
an associated reduction in mucosal interaction of opportunistic enteric pathogens 
(Simpson and Campbell, 2015). 
Insoluble non-digestible substrates are difficult to break down. Only a few species are 
able to degrade them and provide other species with soluble breakdown products (Flint 
A selectively fermented ingredient that 
allows specific changes, both in the 
composition and/or activity in the 
gastrointestinal microflora that confers 
benefits upon host well-being and health 
 17 
et al., 2017). Absence of these primary degrading species means that some substrates 
remain integral with an effect on subsequent degrading species. In rural agrarian 
societies, a high level of faecal SCFA is seen whereas higher consumption of fermentable 
substrate in vegans did not result in such an increase in a dietary intervention in a US 
population (Wu et al., 2016). This may be due to the absence of the primary degraders 
whose activities are required to initiate degradation of these recalcitrant substrates. In 
this way inter-individual differences in gut microbiota composition before a dietary 
intervention can affect responses to dietary change. 
Rat studies with feed supplements with short-chain oligofructose, long-chain inulin, or 
with diets including inulin or arabinoxylan had a variable bifidogenic effect, and, lower 
total SCFA concentrations with caecal pH also significantly decreased compared to the 
control (Simpson and Campbell, 2015). 
Studies with resistant starch that escapes digestion in the small intestine revealed that R. 
bromii and E. rectale increased (Martínez et al., 2010; Walker et al., 2011). However, the 
specific effects depend largerly on the type of resistant starch both in animal and in 
human studies (Simpson and Campbell, 2015). Inulin, another dietary fibre induced an 
increase in the numbers of Bifidobacterium, Lactobacillus/Enterococcus and the 
Atopobium group in one study but in another study no effect was recorded, probably due 
to a different inulin source and the mixing with other fibres (Costabile et al., 2010; 
Linetzky Waitzberg et al., 2012). Bifidobacterium enrichment was confirmed in yet other 
studies using inulin as a prebiotic together with an increase in Faecalibacterium 
prausnitzii or a reduction of Prevotella (Simpson and Campbell, 2015). Oligosaccharides 
increase the number of faecal bifidobacteria (Benus et al., 2010; Cloetens et al., 2010; 
Vulevic et al., 2013; Walton et al., 2012). The levels of the Faecalibacterium prausnitzii 
group and the Roseburia intestinalis group were reduced using (FOS) (Benus et al., 
2010). GOS diminish the number of Bacteroides spp. and Clostridium histolitycum group 
of bacteria (Vulevic et al., 2013). Intake of polydextrose or soluble corn fibre resulted in 
a higher concentration of Clostridiaceae and Veillonellaceae and lower quantity of 
Eubacteriaceae compared with the control (Hooda et al., 2012). The number of 
Faecalibacterium prausnitzii, a butyrate producer known for its anti-inflammatory 
properties, was also elevated after fibre consumption. Another study with polydextrose 
reported an increase of Ruminococcus intestinalis, also a butyrate producer, and 
Clostridium clusters I, II, and IV, while there was a decrease of 
Lactobacillus/Enterococcus (Costabile et al., 2012). The impact of resistant maltodextrin 
was not consistent (Baer et al., 2014). Consumption of arabinoxylan-oligosaccharides-
enriched breads led to increased faecal butyrate (Walton et al., 2012) and elevated 
Lactobacilli levels (Cloetens et al., 2010; Walton et al., 2012).  
Non-starch polysaccharides can also inhibit the adherence of a range of different enteric 
gut pathogens including Salmonella spp., Shigella spp., enterotoxigenic E. coli and C. 
difficile (Simpson and Campbell, 2015). 
6.6 Probiotics 
Probiotics are live microorganisms which when 
administered in adequate amounts confer a health 
benefit to the host (Guarner and Schaafsma, 
1998). Often used probiotic microorganisms are 
Lactobacillus rhamnosus, Lactobacillus reuteri, 
Bifidobacteria and certain strains of Lactobacillus casei, Lactobacillus acidophilus-group, 
Bacillus coagulans, Escherichia coli strain Nissle 1917, certain enterococci, especially 
Enterococcus faecium SF68, and the yeast Saccharomyces boulardii (Pandey et al., 
2015). Probiotic effects are very strain specific and cannot be generalised. 
Fermented foods such as fermented milk or yoghurt contain lactic acid bacteria. Several 
groups have reported increased total bacterial load after regular consumption of 
fermented milk or yoghurt (Singh et al., 2017). Especially Bifidobacteria and/or 
Live microorganisms which when 
administered in adequate amounts 
confer a health benefit to the host. 
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Lactobacilli have been seen to increase. The effect of probiotic VSL#3 consisting of three 
strains of Bifidobacterium, four strains of Lactobacillus, and one strain of Streptococcus in 
a trial with overweight healthy adults, was an increase in total aerobes; anaerobes 
Lactobacillus, Bifidobacteria, and Streptococcuscompared to placebo. These subjects also 
had fewer total coliforms and Escherichia coli, as well as a reduced triglycerides, total 
cholesterol, LDL-cholesterol, very low‑density lipoprotein (VLDL)-cholesterol, and high-
sensitivity C-reactive protein (Rajkumar et al., 2014). High-density lipoprotein (HDL)-
cholesterol and insulin sensitivity improved. In another study enteropathogens E. coli and 
Helicobacter pylori were reduced after Helicobacter-infected children consumed probiotic-
containing yoghurt (Yang and Sheu, 2012). 
Most probiotics do not colonise the host’s gut. Therefore, continuous consumption often 
is necessary to achieve lasting effects. 
6.7 Synbiotics 
Synergistic combinations of pro- and prebiotics are called synbiotics (de Vrese and 
Schrezenmeir, 2008). The term is especially reserved for products in which the prebiotic 
compound(s) selectively favours the probiotic organism(s). 
6.8 Microbiota influencing host appetite 
The gut microbiota not only is influenced by the 
food, they themselves affect the host in his eating 
behaviour. The bidirectional communication 
pathway between the gastrointestinal tract 
microorganisms and the brain is called the 
microbiota-gut-brain axis.  
Signalling pathways may be neural, endocrine and/or immune pathways (Temko et al., 
2017). Microbial-derived metabolites can activate these pathways. They signal from the 
gut to the brain and may impact the brain. Neural signalling from the brain to the gut can 
influence gut function and change the composition and function of the gut microbiota. 
The gut microbiota has a key regulatory role in appetite (van de Wouw et al., 2017). 
Bacterial components and metabolites are able to influence intestinal satiety pathways, 
thus controlling host appetite and satiety. The main actors are the SCFAs acetate, 
propionate and butyrate. The signalling goes via the vagus nerve that connects the 
digestive tract directly with the brain. However, much is still not clear: obesity is 
associated with high levels of SCFAs, while supplementation with SCFAs tends to 
decrease acute food intake. Also, some gut microbes may produce short protein 
sequences that share a sequence that is identical to various appetite-regulating peptides 
(molecular mimicry). 
The gut microbiota can alter host nutrient and taste receptors and therefore taste 
signalling, thereby influencing the host to eat specific nutrients (Alcock et al., 2014). As a 
result, the microbiota’s preferred food substrates increase and thereby survival. It is 
hypothesised that this host-bacteria relation has evolved so as to enhance the individual 
bacteria’s own survival or hinder that of competitive gut bacteria. Another pathway is 
through microbes releasing toxins due to low concentration of growth-limiting nutrients. 
These toxins induce dysphoria leading to increased eating. 
Temko et al. performed a systematic review on the influence of gut microbiota in eating 
disorders and alcohol and substance use disorders (Temko et al., 2017). Eight of the 
reviewed studies dealt with eating disorders. The authors concluded that the studies 
support preliminary evidence for the role of the gut microbiota in these disorders, but 
more is needed to determine causativeness. 
The microbiota-gut-brain axis: 
gut microbiota is influenced by the 
food and affects the host in his 
eating behaviour. 
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7 Effects of/on health and well-being  
 
Dysbiosis -imbalances or alterations in microbial composition or activity- can influence 
health and is implicated in various diseases, such as obesity, type 2 diabetes, asthma, 
allergies and inflammatory bowel disease. 
The microbiota produces signalling molecules and metabolites that influence several 
intestinal functions and various organs. 
Inflammatory bowel disease is clearly associated with intestinal dysbiosis, with reduction 
in biodiversity as well as decreased representation of several specific taxa. 
Data suggest that for type 1 diabetes mellitus, intestinal microbiota might be involved in 
the progression to clinical disease, not initiating the disease process. Several models, 
e.g. the Leaky Gut Hypothesis, the Old Friends Hypothesis, the Perfect Storm Hypothesis 
and the Hygiene Hypothesis link the gut microbiome with the development of type 1 
diabetes.  
The gut microbiota has a key role in the regulation of different metabolic pathways that 
are important in glucose homeostasis and type 2 diabetes pathogenesis.  
Studies support the link between the microbiota and the onset of Coeliac disease, a 
complex multifactorial chronic immune-mediated enteropathy, triggered by the ingestion 
of gluten in genetically susceptible individuals. 
Intestinal microbiota takes part in the development of obesity and subsequent insulin 
resistance.  
Gut microbiota seems to be one of the factors involved in fatty liver diseases associated 
with alcohol, obesity, and the metabolic syndrome. 
While the microbiome can influence cardiovascular diseases indirectly via its effect on 
type 2 diabetes and obesity, speculations about a more direct involvement via the 
metabolism of choline is still under debate. 
Certain bacteria promote carcinogenesis directly by secreting substances that lead to 
DNA damage, whereas others promote carcinogenesis indirectly by maintaining a 
persistent pro-inflammatory microenvironment. 
The most relevant function of the gut microbiome to autoimmunity is maintenance of the 
immune system involving SCFAs, secondary bile salts, and trimethylamines. 
The development of allergies later in life is related to the development of the immune 
system in early life. The factors involved determine the composition of the intestinal 
microbiota that in turn modulates the immune system response. 
Studies in animals suggest a role for gut microbiota in Alzheimer's disease-related 
pathogenesis. In general, the gut-microbiota-brain axis is instrumental for human and 
animal well-being. 
Exercise leads to an increase in microbiota diversity. Exercise early in life, when the 
composition of the microbiota is still evolving, may positively influence this evolution and 
may create lasting adaptations in lean mass and psychological well-being. 
 
Imbalances or alterations in microbial composition or activity – dysbiosis – can influence 
health and is implicated in various diseases. The factors that can disturb the balance of 
intestinal microbiota include: lifestyle, antibiotic treatments and pathogens. Diseases 
such as obesity, type 2 diabetes, asthma, allergies and inflammatory bowel disease 
(IBD), the so-called “diseases of civilisation”, have been associated with dysbiosis of the 
gut microbial ecosystem (Rampelli et al., 2016). There are also associations with 
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inflammatory skin diseases such as psoriasis and atopic dermatitis, autoimmune arthritis, 
and atherosclerosis. 
The microbiota produce signalling molecules and metabolites that influence several 
intestinal functions: visceral-sensing, motility, digestion, permeability secretion, energy 
harvest, mucosal immunity, and barrier effect (Iebba et al., 2016). These products are 
also transported to various organs affecting their functionality: brain (cognitive 
functions), liver (lipid and drug metabolism), and pancreas (glucose metabolism). A gut 
microbiota in an eubiotic status is characterised by a preponderance of potentially 
beneficial species, belonging mainly to the two bacterial phylum Firmicutes and 
Bacteroides, while potentially pathogenic species, such as those belonging to the phylum 
Proteobacteria (Enterobacteriaceae) are present, but in very low relative abundance. In 
the case of dysbiosis this balance is disturbed. Dysbiosis induces an immune reaction 
from the host thereby promoting the dysbiosis status. Inflammation releases components 
in the gut that represent a growth advantage for potentially pathogenic species, such as 
the members of the Enterobacteriaceae family, in particular E. coli. The relative 
abundance of the obligate anaerobe Faecalibacterium prausnitzii, a butyrate producer 
defined as an anti-inflammatory bacterium, is reported to be significantly reduced. The 
ratio of the relative abundances of F. prausnitzii / E. coli is currently used to evaluate the 
dysbiosis status. 
Besides being an energy source, SCFAs can act as signalling molecules (Dolan and 
Chang, 2017; Koh et al., 2016). Butyrate and, to a lesser extent, propionate are known 
to act as inhibitors of histone deacetylases that interfere with chromatin structures and 
gene expression. Butyrate protects against colorectal cancer and inflammation, at least 
partly, by inhibiting histone deacetylases. This inhibiting effect also works anti-
inflammatory making the immune system hypo-responsive to beneficial commensals. 
SCFAs also regulate cytokine expression in T cells (e.g. IL-10) and generation of Tregs 
through histone deacetylase inhibition.  
Acetate and propionate are activators of free fatty acid receptors promoting secretion of 
glucagon-like peptide 1 (GLP-1) and peptide YY (PYY), affecting satiety and intestinal 
transit.  
Butyrate can also modulate the activity of the enteric nervous system modulating gut 
motility. Moreover, SCFAs affect the gut-brain neural axis and regulate the permeability 
of the blood-brain barrier. 
The intestinal mucosa and its immune system maintain a status of tolerance to the 
antigenic stimuli of normal bacterial flora, but intolerance to pathogenic microorganisms 
(Lopetuso et al., 2016). Antigens are continuously presented to the mucosal effector cells 
that react through specific receptors, the pattern recognition receptors. Mucosal injury 
leads to inflammation. Intestinal epithelial cells react to repair the damage, a process 
regulated by cytokines. Several factors among which SCFAs and also gut microbiota, 
through the activation of TLRs, regulate intestinal epithelial cells’ proliferation. 
There is also an indication that gut microbiota may promote metabolic inflammation 
through TLR signalling upon challenge with a diet rich in saturated lipids (Caesar et al., 
2015). 
Communication between the liver and the intestine is facilitated by bile acids (Betrapally 
et al., 2016; Dolan and Chang, 2017). Bile acids are formed in the liver from cholesterol 
to facilitate digestion of fats. Bile acids are further transformed in the intestine by 
bacteria. They furthermore act as ligands for receptors that include nuclear receptor 
Farnesoid X receptor (FXR) and G protein-coupled bile acid receptor 1 (GPBAR1). FXR 
functions in a negative feedback pathway in which synthesis of bile acids is inhibited 
when cellular levels are already high. GPBAR1 regulates bile acid homeostasis, glucose 
homeostasis, energy metabolism as well as inflammation. The bile acid composition in 
the intestine determines the microbiota composition. 
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7.1 Inflammatory bowel disease 
Inflammatory bowel disease (IBD) represents a heterogeneous group of chronic immune-
mediated inflammatory diseases affecting the gastrointestinal tract (Lane et al., 2017). 
There are two major types: ulcerative colitis (UC) and Crohn’s disease (CD). 
IBD is a disease arising from both genetic and environmental factors (diet, smoking, 
stress, sleep patterns, hygiene, and antibiotic use) with the host genome potentially 
having a pivotal role in shaping the gut microbiota (Parekh et al., 2015). Research more 
and more demonstrates that the interaction between diet and microbes in a susceptible 
person contributes significantly to the onset of the disease (Dolan and Chang, 2017). IBD 
patients are thought to have a compromised mucus layer in the intestine, thus allowing 
luminal microflora to penetrate intraepithelial cells and drive inflammatory and 
proliferative processes. IBD is clearly associated with intestinal dysbiosis, with reduction 
in biodiversity as well as decreased representation of several specific taxa, including 
Firmicutes and Bacteroidetes (Lane et al., 2017; Lopetuso et al., 2016). A relative 
increase in the abundance of Enterobacteriaceae, including E. coli and Fusobacterium is 
noted. The presence in the mucus layer of Pasteurellaceae (Haemophilus sp.), Veillonella 
parvula, Neisseriacaea corrodens, and Fusobacteriaceae nucleatum positively correlates 
with the diagnosis of CD (Parekh et al., 2015). Also, fungal and yeast communities have 
increased diversity in CD including Saccharomyces cerevisiae, Calvispora lusitaniae, 
Cyberlindnera jadinii, Candida albicans, and Kluyveromyces marxianus (Lane et al., 
2017; Lopetuso et al., 2016). In contrast, fungal biodiversity is reduced UC (Gilca et al., 
2017).  
In a meta-analysis, exposure to antibiotics during childhood reorganising the microbiota 
composition, was shown to be associated with increased risk of CD but not UC (Ungaro et 
al., 2014). 
Microbiota is able to sustain mucosal healing and regeneration through various 
mechanisms (Lopetuso et al., 2016). An alteration in microflora composition, as in IBD, 
can sustain intestinal damage. In new-onset CD, the degree of dysbiosis is greater in ileal 
or rectal mucosal biopsies than in stool (Dolan and Chang, 2017; DuPont, 2014). The 
contact of mucosal bacteria with host tissues allows to regulate local immunity. If this 
balance is disrupted also the immune response is changed. Also eukaryotes like 
Saccharomyces spp. have a regulatory effect on dendritic cells, modulating various anti-
inflammatory cytokine production in this way influencing IBD (Gilca et al., 2017). 
The SCFAs acetate, butyrate and propionate are pivotal in several host physiological 
aspects such as nutrient acquisition, immune function, cell signalling, proliferation control 
and pathogen protection. SCFA levels are considered anti-inflammatory and important for 
maintenance of the mucosal barrier. Butyrate has a positive effect on cell proliferation, 
differentiation and maturation after epithelial injury (Lopetuso et al., 2016). Several 
studies have demonstrated that IBD patients possess lower faecal counts of Roseburia 
and other butyrate-producing bacteria than healthy subjects (Dolan and Chang, 2017; 
Lopetuso et al., 2016). Another butyrate producer Faecalibacterium prausnitzii is 
dramatically less abundant in CD patients (Dolan and Chang, 2017; DuPont, 2014). 
Healthy subjects, on the other hand, have 10-fold more abundant Eubacterium rectale in 
their intestines (Singh et al., 2017). A diet high in fruits and vegetables resulting in more 
SCFAs, reduces the risk of developing CD (Dolan and Chang, 2017; Lane et al., 2017). 
Bacterial bile acid metabolism allows for signalling via bile acid receptors, promoting anti-
inflammatory signalling and barrier function (Dolan and Chang, 2017). Normally bile 
acids are first deconjugated by bile salt hydrolase of the microbiota prior to further 
metabolism. In IBD patients higher concentrations of sulphated and conjugated bile acids 
are found in their stool than in healthy controls due to a decrease of Firmicutes-
associated bile salt hydrolase genes. This results in a loss of anti-inflammatory 
properties.  
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Also in irritable bowel syndrome (IBS) the gut microbiota, the bidirectional gut–brain axis 
and inflammation play a role (DuPont, 2014). Several studies have supported that 
intestinal infection was strongly associated with a subsequent emergence of symptoms. 
7.2 Diabetes 
In type 1 diabetes there is a shortage of pancreatic β-cells, that produce insulin, due to 
autoimmune destruction. Type 2 diabetes is characterised by a low level of insulin 
receptors and/or insulin resistance due to a defect in the insulin cascade.  
The first stages of type 1 diabetes typically develop early in life. The gut microbial 
community is then shaped influenced by factors such as host genetics, mode of delivery, 
diet and external factors such as treatment with antibiotics. The gut microbiota on its 
turn has a role in shaping the immune system early in life. The gut microbiota in 
individuals with preclinical type 1 diabetes mellitus is characterised by a high level of 
Bacteroidetes, a lack of butyrate and lactate-producing bacteria, reduced bacterial and 
functional diversity and low community stability (Knip and Siljander, 2016). Though, it 
seems that autoantibodies that are predictive of type 1 diabetes mellitus come first. The 
changes appear afterwards. This suggests that the intestinal microbiota might be 
involved in the progression to clinical disease, not initiating the disease process itself. 
The process leading to type 1 diabetes mellitus is often initiated during the first few years 
of life, when the intestinal microbiota undergoes dynamic development.  
Most of the studies that are available only point to a correlation without determining 
causal relationships between the gut microbiota and preclinical or clinical Type 1 diabetes 
mellitus (Endesfelder et al., 2016; Knip and Siljander, 2016). Many studies rely on mice 
and rats that develop autoimmune diabetes mellitus after exposure to certain chemicals 
or viruses (Knip and Siljander, 2016). In humans, a Finnish study with children reported 
a shortage of the two most abundant Bifidobacterium species (B. adolescentis in the 
elder children and B. pseudocatenalatum in the younger children) and an increased 
abundance of Bacteroides compared with the controls. However, a German study with 
children between 3 months and 3 years did not see any differences, whereas a Finnish 
study examining the stools of children in the same age group did see an increase in 
Bacteroides levels. Other studies point to a similar evolution in bacterial presence. Also, a 
lower number in butyrate-producing bacteria and mucin-degrading species next to a drop 
in diversity are reported (Endesfelder et al., 2016).  
Several models have been proposed linking the gut microbiome with the development of 
type 1 diabetes (Endesfelder et al., 2016). According to the Leaky Gut Hypothesis, 
increased permeability of the gut epithelium results in diet-derived macro-molecules and 
microbial antigens passing the epithelial barrier and consequently triggering intestinal 
inflammation possibly leading to pancreatic β-cell attack. A decreased number of 
butyrate-producing bacteria may be the cause. The Old Friends Hypothesis builds on the 
co-evolution of host and commensals. A lack of encounter with co-evolved commensal 
bacteria might substantially influence self/non-self-recognition patterns in the immune 
system. The Perfect Storm Hypothesis combines both models. The Hygiene Hypotheses 
claims that increasing type 1 diabetes incidences being observed in Western societies 
result from a lack of contact with infectious agents due to increased hygienic conditions. 
Lack of pathogenic encounter in early childhood, disrupts proper priming of the immune 
system, possibly resulting in over-reaction leading to autoimmunity. A shift in the 
butyrate production may be the key driver induced by diet, drug treatment, mode of 
delivery, etc. 
The gut microbiota has a key role in the regulation of different metabolic pathways that 
are important in glucose homeostasis and type 2 diabetes pathogenesis (Muscogiuri et 
al., 2016). Several studies in mice have shown that diabetic obese mice showed a higher 
abundance of Firmicutes, Proteobacteria, and Fibrobacteres phyla compared to lean mice. 
Some probiotic strains (Lactobacillus or Bifidobacterium) are able to modulate the 
glucose homeostasis. This is also seen in humans. Also, a low percentage of bacterial 
 23 
Clostridia species that are butyrate producing bacteria, was noticed in type 2 diabetes 
humans. Butyrate produced by certain bacteria prevents translocation of endotoxic 
compounds derived from the gut microbiota, which have been shown to drive insulin 
resistance.
 
Figure 5. The gut microbiota plays an important role in the onset of type 2 diabetes 
(© Muscogiuri / Taylor & Francis, source: Muscogiuri et al., 2016) 
The incretin hormones GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) 
stimulate insulin secretion and regulate postprandial glucose excursions, whereas GLP-1, 
cholecystokinin (CCK), and PYY inhibit appetite and food intake (Muscogiuri et al., 2016). 
The incretin hormones are required to maintain an adequate β-cell mass in adulthood 
and to maintain normal β-cell responses to glucose. In patients with type 2 diabetes this 
hormone action is reduced. Gut bacteria normally stimulate the production of these 
hormones. 
7.3 Coeliac disease 
Coeliac disease is a complex multifactorial chronic immune-mediated enteropathy, 
triggered by the ingestion of gluten in genetically susceptible individuals (Cenit et al., 
2016). The majority of genetically susceptible individuals does not develop disease upon 
gluten exposure indicating that other factors play a role too. Studies support the link 
between the microbiota and the disease onset. Environmental factors may shape the 
composition of the microbiota, especially in early life: gestation mode, feeding pattern, 
infections, antibiotics and others. Dysbiosis in coeliac disease means an increase in gram-
negative and Bacteroidetes species, and a decrease in Bifidobacteria and Lactobacilli 
(Losurdo et al., 2016). An unfavourable microbiota could amplify the immune response 
to gliadin. The probiotic Bifidobacterium longum was able to decrease this effect. 
Bifidobacterium strains are able to reduce the mucosal production of pro-inflammatory 
cytokines, notably tumour necrosis factor-α and IL-10. 
However, the precise gut microbiota alterations that may precede disease onset are not 
known. 
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7.4 Obesity 
Obesity results from the accumulation of excess adipose tissue. Causes include 
behavioural and environmental factors, such as excessive consumption of energy-dense 
foods and a sedentary lifestyle. But also intestinal microbiota turned out to take part in 
the development of obesity and subsequent insulin resistance (Villanueva-Millan et al., 
2015). 
Gut microbes ferment dietary polysaccharides resulting in the production of 
monosaccharides and SCFAs, that are absorbed and act as an energy source for the host. 
Microbiota from obese individuals has an increased capacity to harvest energy from the 
diet. In the obese population an increase in fermentation by the gut microbiota is seen. A 
high ratio of Bacteroides to Prevotella shows a decrease in SCFAs. A high ratio of 
Firmicutes to Bacteroides/Prevotella as in obese individuals enriches the microbial genes 
involved in polysaccharide degradation and increases the SCFA levels (Cardinelli et al., 
2015; Parekh et al., 2015). The increase in Firmicutes is mainly the result of an 
increased abundance of Clostridium cluster XIVa, which contains many butyrate-
producing species such as Faecalibacterium prausnitzii (Villanueva-Millan et al., 2015). 
Other studies found no alteration or even an increase in Bacteroidetes compared to lean 
persons.  
While these are contradicting results, the lower species diversity and the presence of 
more aerotolerant bacteria in obese persons have been clearly demonstrated (Villanueva-
Millan et al., 2015). Aerotolerant bacteria generate products that are easily converted to 
SCFAs. While there is no consensus on the specific pattern, alterations in gut bacteria are 
definitely involved in obesity. 
Microbiota also influences the host’s lipid metabolism through various mechanisms 
(Cardinelli et al., 2015). The microbiota can induce lipogenesis. Also, microbiota 
decreases expenditure of energy by decreasing fatty acid oxidation which, in turn, 
favours lipid deposition and storage in adipose tissue, liver, and/or muscle. 
Butyrate, propionate, and acetate also regulate gut hormones. Through their specific free 
fatty acid receptors SCFAs regulate satiety and intestinal motility. Gut microbiota after 
each meal stimulate intestinal L-cells to excrete GLP and PYY that regulate satiety. PYY 
levels are negatively correlated with the tendency to obesity. GLP-1 stimulates insulin 
secretion from β-cells of the islets of Langerhans.  
Obesity is accompanied by a low-grade inflammatory response. TLRs are a type of 
pattern recognition receptor for microbe-associated molecular patterns seen on bacteria, 
viruses, and fungi (Parekh et al., 2015). They recognise microorganisms as pathogenic or 
non-pathogenic. Normally gut microbiota induces anti-inflammatory effects that protect 
epithelial cells against pathogens via TLRs. TLR4 interacts with lipopolysaccharides (LPS, 
a determinant of Gram-negative bacteria cells, that normally circulate at low 
concentrations in the blood). This interaction plays a role in inflammation following a high 
fat diet by disrupting the intestinal epithelium and barrier (Villanueva-Millan et al., 2015). 
Once LPS is in the blood it can induce cellular inflammatory responses in several 
tissues/organs. The interaction between gut microbiota and TLR-5 results in the induction 
of inflammatory cascade and downstream transcription of various cytokines and 
inflammatory mediators resulting in a low-grade inflammatory state associated with 
obesity (Parekh et al., 2015). Other molecules (TLR2, myeloid differentiation primary 
response gene 88, nuclear oligodimerisation receptor) are also being studied (Villanueva-
Millan et al., 2015). 
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Figure 6. Gut microbiota and its influence on obesity 
(© Parekh / Springer Nature, source: Parekh et al., 2015) 
7.5 Liver disease 
Fatty liver diseases are associated with alcohol, obesity, and the metabolic syndrome. 
Diet and lifestyle together with the gut microbiota are involved, but the mechanisms of 
pathogenesis are not yet elucidated. Most knowledge is derived from animal 
experiments.  
Non-alcoholic fatty liver disease (NAFLD) is characterised by fat accumulation, mainly as 
triglycerides, in the hepatocytes. It can progress to non-alcoholic steatohepatitis (NASH), 
liver cirrhosis, and hepatocellular carcinoma. The underlying pathogenesis of NAFLD and 
NASH is not clear, but alterations in gut microbiota are thought to be a major contributor 
to its development (Betrapally et al., 2016; Leung et al., 2016; Parekh et al., 2015). 
Studies show there is a significant increase in faecal volatile organic compounds, that 
affect the liver. Some studies report disproportionately low levels of bacteria from the 
Ruminococcaceae family (Firmicutes) and high levels of Escherichia, while others report 
lower levels of Bacteroides and high levels of Firmicutes (e.g. Clostridium coccoides).  
Several mechanisms may lead to NAFLD/NASH (Figure 7). A higher amount of SCFA, as 
in obese, due to an increase in the Firmicutes to Bacteroidetes ratio, leads to a higher 
energy harvest inducing lipogenesis and gluconeogenesis in the liver. Dysbiosis also 
reduces butyrate production in favour of other SCFAs. Less butyrate decreases fasting-
induced adipocyte factor (FIAF) secretion from intestinal cells, leading to activation of 
lipoprotein lipase (LPL) and subsequent triglyceride accumulation in both adipose tissue 
and the liver. LPS, an endotoxin found on the cell membrane of Gram-negative bacteria, 
binds to LPS-binding protein and CD14 and then activates TLR-4. TLR-4 in turn initiates a 
pro-inflammatory cascade. Bile acids suppress overgrowth of bacteria in the gut. A low 
level may result in small intestinal bacterial overgrowth (SIBO) that induces alterations of 
gut permeability and is also associated with NAFLD/NASH. Patients with NASH have an 
increased abundance of ethanol-producing bacteria such as Escherichia coli in their gut. 
Ethanol might contribute to liver injury by increasing intestinal permeability and portal 
LPS levels. Another mechanism is the catalysis of choline, a phospholipid component of 
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the cell membrane, by the gut microbiota into toxic methylamines. Hepatic uptake of 
these toxic metabolites results in the induction of the inflammatory cascade. 
 
Figure 7. Gut microbiota and its influence on non-alcoholic fatty liver disease (NAFLD) and non-
alcoholic steatohepatitis (NASH) proposed mechanisms. 
(© Leung / Springer Nature, source: Leung et al., 2016). 
Alcohol-induced dysbiosis could lead to alcoholic liver disease (ALD) (Pevsner-Fischer et 
al., 2016). Excessive alcohol intake leads to an overgrowth of Gram-negative bacteria, 
that cause increased gut permeability, in turn leading to increased availability of bacterial 
metabolites to the liver, as well as pro-inflammatory molecules such as bacterial toxins, 
LPS and even living microbes. Alcohol also affects the composition of bile acids 
(Betrapally et al., 2016). 
7.6 Cardiovascular disease 
Traditional risk factors leading towards the development of cardiovascular disease (CVD), 
are mainly type 2 diabetes and obesity (Garcia-Rios et al., 2017). The role of microbiota 
in these conditions has been described above. 
The metabolism of choline into trimethylamine (TMA) and TMAO by the gut microbiota 
also plays a role here (Griffin et al., 2015; Tuohy et al., 2014). L-carnitine derived from 
red meat may also be transformed into TMA and TMAO by microbes. TMAO also impacts 
on bile acid metabolism in the liver at multiple levels including cholesterol transporters 
and suppression of bile acid synthetic enzymes. TMAO seems to be correlated with 
subsequent CVD occurrence, though a causative relation is still under debate.  
7.7 Cancer 
Certain bacteria promote carcinogenesis directly by secreting substances that lead to 
DNA damage (Hold, 2016; Lv et al., 2017). Examples are Helicobacter hepaticus, 
Enterococcus faecalis, and Bacteroides fragilis. Other bacteria promote carcinogenesis 
indirectly by maintaining a persistent pro-inflammatory microenvironment. An example is 
Fusobacterium nucleatum that increases the permeability of colonic epithelial cells.  
When compared with healthy people, patients with colorectal cancer (CRC) have higher 
amounts of Enterococcus, Escherichia, Klebsiella, and Streptococcus, and lower amounts 
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of Rothia and butyrate-producing bacteria (Lv et al., 2017). People susceptible to CRC 
have more species that generate secondary bile acids, but fewer that produce butyrate. 
Especially the bile acids lithocholic and deoxycholic acid can be proinflammatory. Chronic 
inflammation is a well-established risk factor for CRC. As such, the presence of IBD 
increases the risk of CRC. SCFAs have a protective role in colonic inflammation through 
signalling via GPCRs (Hold, 2016; Koh et al., 2016). Butyrate especially functions as a 
tumour suppressor in colon. Nonetheless, butyrate might have a pro-carcinogenic effect 
on CRC as demonstrated in different animal models (Hold, 2016). 
In the development of CRC genetic alterations drive the progression of normal mucosa to 
pre-malignant lesions (adenomatous polyps) (Hold, 2016). However, not all 
adenomatous polyps become cancerous (adenoma-carcinoma sequence). In CRC 
progression, the involvement of the gut microbiota has been clearly demonstrated in 
numerous animal studies. Cancer progression is not attributable to specific species but 
rather to the metabolic functions and/or pathways of the microbiota as a whole. 
Also, the liver is influenced by the nutrients, metabolites and also toxins and pathogens 
derived from the gut via the portal vein. Often chronic infections by hepatitis B virus 
(HBV) and hepatitis C virus (HCV) and diseases such as ALD and NAFLD lead to 
hepatocellular carcinoma (HCC). Gut microbiota can both influence the development of 
these diseases and the transition from these diseases into HCC (Pevsner-Fischer et al., 
2016). TLR4 signalling activated by the LPS on Gram-negative bacteria, as in ALD, is 
crucial in the dedifferentiation of hepatocytes. In obese persons, a high-fat diet induces 
overgrowth of Gram-positive bacteria that can produce the secondary bile acid 
deoxycholic acid (DCA). DCA is known to cause DNA damage through the production of 
reactive oxygen species, as well as to promote liver carcinogenesis. 
Dysbiosis and intestine mucosal injuries enhance HCC progression (Lv et al., 2017). 
Adjusting the gut microbiota may alleviate the symptoms of liver cancer. Also, the oral 
administration of probiotics protects the mucosa and microbiota homeostasis. They help 
to prevent inflammatory responses and support the differentiation of immune cells 
thereby changing the tumour microenvironment and inhibiting the growth of cancer cells. 
However, the authors ask for more clinical trials to study the exact role of microbiota and 
probiotics in HCC. 
The interaction between the mucosal immune system and gut microbiota is important. In 
remedying dysbiosis the focus shifts from studying individual enterobacterial roles to 
considering gut microbiota as “a microbial community effect” (Yamamoto and 
Matsumoto, 2016). 
7.8 Autoimmune disease 
The most relevant function of the gut microbiome to autoimmunity is maintenance of the 
immune system involving SCFAs, secondary bile salts, and trimethylamines (Coit and 
Sawalha, 2016). SCFAs have an atheroprotective role by signalling through GPCRs (e.g., 
GPR43, GPR41 and GPR109A), and by inhibiting histone deacetylases (HDACs) and thus 
permitting gene transcription (Abdollahi-Roodsaz et al., 2016). The level of medium-
chain fatty acids (MCFAs) is decreased in the intestinal lumen of patients with psoriasis. 
Their role is still unknown. Bile acids act via the FXR and the transmembrane GPCR 
TGR5. Disturbed bile acid metabolism has effects on adiposity, obesity and the metabolic 
syndrome that are all risk factors for some rheumatic diseases. Lastly, choline 
metabolites generated by the microbiota potentially have a causative relationship with 
the pathogenesis of atherosclerosis and cardiovascular disease. 
 28 
 
Figure 8. Immune and disease-modulating capabilities of intestinal microbial metabolites and 
probiotics. (NASH, nonalcoholic steatohepatitis; PPARγ, peroxisome proliferator-activated receptor 
γ; SRA‑1, scavenger receptor A-1; TMAO, TMA N-oxide)  
(© Abdollahi-Roodsaz / Springer Nature, source: Abdollahi-Roodsaz et al., 2016) 
Abdollahi-Roodsaz and colleagues (2016) provide a view on immune and disease-
modulating capabilities of intestinal microbial metabolites and probiotics (Figure 8). The 
intestinal microbiota converts dietary fibres into SCFAs and MCFAs, primary bile acids 
into secondary bile acids, and choline derivates into TMA. SCFAs act through various 
GPCRs to inhibit HDACs and alter the biology of Treg cells and dendritic cells or to 
activate the inflammasome. Secondary bile acids activate the transmembrane GPCR 
TGR5 and the FXR, inducing the T3 thyroid hormone and fibroblast growth factor 19 
(FGF19), respectively. These pathways and their end products modulate a variety of 
inflammatory, metabolic and autoimmune diseases. Probiotics support the host’s immune 
system, enhance intestinal barrier function and limit enteric pathogens. The dark blue 
colour boxes highlight rheumatic diseases that might be affected by the intestinal 
microbiota. These diseases include gout, psoriatic arthritis (PsA), rheumatoid arthritis 
(RA) and osteoarthritis (OA).  
7.9 Allergy 
Both genetic and environmental factors determine the occurrence of allergic disorders, 
including asthma, hay fever, and other types of allergic rhinitis, atopic dermatitis, 
urticaria, and food allergy. The development of allergies later in life is related to the 
development of the immune system in early life (Rachid and Chatila, 2016; Vuitton and 
Dalphin, 2017). Factors that are involved include the mode of delivery, number of 
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siblings, history of infection in mother and child, antibiotic treatments, exposure to pets 
and indoor allergens, and dietary components such as breast feeding, early food 
diversification, and regular consumption of fermented foods. These factors determine the 
composition of the intestinal microbiota that in turn modulate the immune response. 
Acinetobacter lwoffii F78, Lactococcus lactis G121, and Bacillus licheniformis might be 
candidates for use in allergy prevention.  
In asthma an inadequate immune regulation and/or compromised airway epithelium 
result in an allergic airway disease. SCFA’s modulation of HDACs and GPCR-induced 
signalling can be important for shaping the immune niche in the lungs (Koh et al., 2016). 
In the concept of a “common mucosal response” antigen presentation at a single mucosal 
site stimulates lymphoid cell migration to other mucosal sites, thus influencing the 
immune responses of remote sites (systemic immunity) (Ipci et al., 2017). A reduced 
density and diversity of Bacteroidetes, producers of butyrate that help in establishing the 
immune system in early infancy precedes the development of allergies. At the onset of 
allergic symptoms, the microbiota of allergic children shows lower counts of Akkermansia 
muciniphila, Faecalibacterium prausnitzii, and Clostridium spp., a higher prevalence of 
Bifidobacterium adolescentis, lower levels of Bifidobacterium catenulatum and 
Staphylococcus aureus; and decreased bacterial diversity overall. 
Food allergies coincide with low species diversity, reduced Clostridiales, and increased 
Bacteroidales (Hirata and Kunisawa, 2017). Not only SCFAs but also long-chain fatty 
acids (LCFAs) are acting as energy sources as well as in the regulation of immune 
responses. Omega-3 and omega-6 fatty acids have anti-allergic and anti-inflammatory 
properties. Commensal bacteria participate in LCFA metabolism. e.g. epithelial barrier 
function is enhanced by Lactobacillus-derived 10-hydroxy-cis-12-octadecenoic acid 
preventing food allergy. Microbiota also act through the production of essential vitamins. 
Besides nutritional functions they exercise immunologic functions, especially folate 
(vitamin B9) and riboflavin (vitamin B2). 
Members of the Clostridium clusters XIVa, XIVb and IV may be protecting against some 
food sensitisation (Rachid and Chatila, 2016). The mechanism involves modulating the 
innate lymphoid cells. A second mechanism targets the adaptive immune response to 
promote tolerance. The commensal microbiota acts directly on Treg cells through their 
toll-like receptors and on the β cells. 
It is not clear whether Staphylococcus aureus, commonly found on the skin of eczema 
sufferers, is cause or effect of the development of eczema (Marrs and Flohr, 2016). 
However, here too a diminished diversity of gut microorganisms in early live precedes the 
onset of eczema, together with greater prevalence of Clostridium species.  
7.10 Alzheimer's disease 
Studies in animals suggest a role for gut microbiota in Alzheimer's disease-related 
pathogenesis (Jiang et al., 2017). The bidirectional communication system, the 
microbiota-gut-brain axis, includes neural, immune, endocrine, and metabolic pathways. 
Dysbiosis increases the permeability of the gut and blood-brain barrier. Bacteria can also 
secrete large amounts of amyloids and LPS, interfering with signalling pathways and the 
production of pro-inflammatory cytokines associated with Alzheimer's disease. 
7.11 Mental health 
Again, the gut-microbiota-brain axis is instrumental for human and animal well-being 
(Sherwin et al., 2016). Dysfunction of the microbiome-brain-gut axis has been implicated 
in stress-related disorders such as depression and anxiety and in neurodevelopmental 
disorders such as autism (Borre et al., 2014). Inflammatory mediators (various cytokines 
and chemokines) produced by microbes may affect the gut epithelium integrity, infiltrate 
and induce an immune response (Figure 9). Also, neurotransmitters and SCFAs that have 
neuroactive properties, are produced by the gut microorganisms. Tryptophan is an 
essential amino acid which is the precursor of serotonin, kynurenine, and metabolites of 
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the kynurenine that are neuroactive as well. The gut microbiota may affect the rate of 
the tryptophan metabolic pathway (Kennedy et al., 2016). Specific bacterial species, can 
regulate central neurotransmitter levels and receptor expression. 
 
Figure 9. The microbiome-brain-gut axis and its variety of pathways. (ACTH, adrenocorticotropin 
hormone; CRH, corticotropin-releasing hormone; GABA, gamma-aminobutyric acid; HPA, 
hypothalamic-pituitary-adrenal; SFCAs, short chain fatty acids).  
(© Kennedy / Macmillan Publishers Limited, Source: Kennedy et al., 2016) 
Psychiatric conditions such as depression and anxiety can be traced back to deficits in 
serotonergic neurotransmission, alterations in the brain derived neurotrophic factor, 
immune activation, and dysregulation of the hypothalamic-pituitary-adrenal axis 
(Sherwin et al., 2016). The gut microbiota regulates all of these biological parameters. In 
depressed individuals increase in bacterial diversity was shown, with a decrease in the 
level of Firmicutes and an increase in Proteobacteria, Actinobacteria, and Bacteroidetes. 
An increased microbial diversity in depression may suggest the presence of harmful 
bacteria. There are indications that prebiotics and probiotics may be used as 
antidepressants. 
Also in the pathophysiology of autism spectrum disorders gut microbiota may have a role 
by influencing neurodevelopment, as preclinical and clinical evidence suggests (Kennedy 
et al., 2016). Cognitive decline during ageing is associated with heightened immune 
activity and hypothalamic-pituitary-adrenal axis dysfunction, that in turn is related to the 
changing composition of gut microbiota, as seen above. But cognitive function in general 
encompassing the life-long process of learning, both long- and short-term processes, is 
influenced by the intestinal microorganisms (Gareau, 2016). 
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As consumed food has a central role in programming gut microbiota composition, 
diversity, and functionality throughout life, a diet rich in polyphenols, omega-3 
polyunsaturated fatty acids, prebiotics and probiotics, may help maintain normal brain 
function and mental health (Kennedy et al., 2016).  
7.12 Exercise 
Exercise leads to an increase in microbiota diversity. Athletes show lower levels of 
Bacteroidetes and greater amounts of Firmicutes than non-athletes. However, this effect 
may also be induced by differences in diet. Studies show that several immune responses 
are suppressed during prolonged periods of intense exercise training, causing an acute-
phase inflammatory response. Also, the permeability of the gastrointestinal epithelial wall 
increases and the gut mucous thickness decreases leading to pathogens or endotoxins 
(e.g. LPS) crossing the intestinal barrier into the bloodstream (endotoxemia) triggering 
immune and inflammatory responses. An adequate gut microbiota composition in 
athletes and their resulting SCFA metabolites could neutralise these phenomena.  
Endurance exercise has a profound impact on oxidative stress, intestinal permeability, 
muscle damage, systemic inflammation, and immune responses (Mach and Fuster-
Botella, 2017) leading to gastrointestinal disturbances, anxiety, depression, and 
underperformance (Clark and Mach, 2016). 
Microbiota has a role in oxidative stress modifying the activity of the antioxidant enzymes 
thereby reducing exercise-induced fatigue. Gut microorganisms can regulate the 
hypothalamus-pituitary-adrenal axis that affects the stress response, through the 
synthesis of hormones and neurotransmitters (Clark and Mach, 2016). They also 
maintain a proper hydration state during exercise influencing the cellular transport of 
solutes through the gut mucosa (Mach and Fuster-Botella, 2017). Athletes usually 
consume high amounts of simple carbohydrates and proteins and low amounts of fat and 
fibre in order to provide a quick source of energy (Clark and Mach, 2016). Nevertheless, 
these diets do not promote a healthy gut microbiota composition nor do they produce 
beneficial SCFA. High protein diets can also affect the microbiota composition. They then 
ferment amino acids in the colon producing undesirable metabolites (e.g. phenol, 
hydrogen sulfide and amines) and urea. Athletes in general do not consume sufficient 
fibre and resistant starch for commensal bacteria to produce beneficial SCFAs and active 
neurotransmitters, and at the same time to inhibit the bacteria from producing harmful 
metabolites from proteins. Taking probiotics regularly may shift the microbial 
composition in a positive direction, but it is not clear yet which strains would be beneficial 
for athletes. They also may counteract anxiety and depression. 
Exercise early in life when the composition of the microbiota is still evolving may 
positively influence this evolution and may create lasting adaptations in lean mass and 
psychological well-being. (Mika and Fleshner, 2016). Early-life exercise increases 
Bacteroidetes and decreases Firmicutes. As neural circuits are in full development in 
young children, exercise through the impact of commensals can protect the brain against 
stress-induced psychiatric disorders, such as depression and anxiety later in life. 
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8 Effects of/on infections 
 
When a pathogen infects a host, both the host-pathogen interaction and the microbiota 
are essential. 
When the normal intestinal microbiota is disrupted (e.g. by an antibiotic treatment), 
naturally residing bacteria may become harmful. 
Microbiota influence infection directly by inhibiting or promoting colonisation, and 
indirectly via the immune system. 
When a pathogen is infecting a host, it is not only the host-pathogen interaction that is at 
play, but also the microbiota which plays an essential role. Host and microbiota depend 
on each other for their metabolism. Disruption of the microbiota community disrupts this 
relationship and this may lead to infection (Leslie and Young, 2015). 
Clostridium difficile is a natural resident of the intestinal microbiota; however, it becomes 
harmful when the normal intestinal microbiota is disrupted, and overgrowth and toxin 
production occur. Theriot and Young found that antibiotic induced changes in the 
microbiota shift the caecal metabolome to one that supports Clostridium difficile 
colonisation, including bile acids, carbohydrates and amino acids (Theriot and Young, 
2014). Bile acids produced by the host are normally converted by the microbiota into 
secondary bile acids. Disruption of the microbiota may lead to increased levels of primary 
bile acids in the large intestine, giving an advantage for germination of C. difficile spores 
(Leslie and Young, 2015). 
Carbohydrate fermentation lowers colonic pH (5.5–6.5 in proximal colon where 
fermentation is highest, compared to pH 6.5–7.0 in the distal colon) and inhibits growth 
of Gram-negative Enterobacteriaceae including familiar pathogens Salmonella spp. and E. 
coli (Simpson and Campbell, 2015). 
Also, bacteria-bacteria interaction is key. One way that bacteria gain a competitive 
advantage is via production of microbial products such as bacteriocins. Lactic acid 
bacteria and others produce bacteriocins in order to combat other bacteria. Also, 
pathogens must compete with resident microbes for the nutrients. E. coli strain Nissle 
1917 provides colonisation resistance to infection by Salmonella enterica serovar 
typhimurium by competing for iron (Leslie and Young, 2015). 
Besides this direct effect inhibiting or promoting colonisation, the microbiota also 
indirectly influences infection via the immune system. A diversity of bacterial signals 
modulate host immunity (Leslie and Young, 2015). Butyrate produced by the microbiota 
aids in the development of peripheral anti-inflammatory T regulatory cells. Some 
bacterial taxa drive intestinal Treg development, whereas others induce Th17 T cell 
development (Caballero and Pamer, 2015). 
Studies with germ-free mice underscore the importance of the microbiota in the defence 
against pathogens (Costa et al., 2016). Germ-free mice were more susceptible to 
Cryptococcus gattii infection and showed reduced levels of IFN-gamma, IL-1 beta and IL-
17, and lower NF kappa B p65 phosphorylation compared to conventional mice.  
Th17 immunity is regulated by the intestinal microbiota composition, especially by 
segmented filamentous bacteria, not only in the gastrointestinal tract, but also in the 
lungs (Gauguet et al., 2015). The authors challenged mice with methicillin-resistant 
Staphylococcus aureus. Higher cytokine IL-22 levels and type 17 immune effector levels 
in the lung were reported in the presence of segmented filamentous bacteria.  
In another study with germ-free mice it was shown that the lack of the microbiota 
influences Salmonella colonisation of the mesenteric lymph nodes (Fernandez-Santoscoy 
et al., 2015). IFN-gamma in the mesenteric lymph nodes of infected germ-free mice 
increased due to the absence of commensals at the time of infection but also due to the 
lack of immune signals provided by the microbiota from birth. 
 33 
A study examining the influence of acidic oligosaccharides derived from pectin on 
Pseudomonas aeruginosa infection demonstrated again the involvement of the microbiota 
(Bernard et al., 2015). Next to other effects, pectin derived acidic oligosaccharides 
modified the intestinal microbiota by stimulating the growth of species involved in 
immunity development, such as Bifidobacterium spp., Sutturella wadsworthia, and 
Clostridium cluster XIVa organisms, and at the same time increased the production of 
butyrate and propionate. 
The human gut microbiota composition was investigated before, during, and after natural 
Campylobacter infection comparing individuals who became culture positive for 
Campylobacter and those who remained negative (Dicksved et al., 2014). Individuals 
who became Campylobacter positive had a significantly higher abundance of Bacteroides, 
Escherichia, Phascolarctobacterium and Streptococcus species. The Campylobacter-
negative group, had more Clostridiales, unclassified Lachnospiraceae and Anaerovorax. 
For the Campylobacter-positive group this resulted in long-term changes in the 
composition.  
The use of antibiotics may have a strong or mild effect on the composition of the 
microbiome depending on the type of antibiotic and the time of treatment in life. In 
young children, the microbiome is still developing. Antibiotics therefore may have a 
lifelong negative effect. In adults, the microbiome usually recovers very well, but even 
then, some bacterial groups may not recover with permanent effects on health. Khanna 
and Pardi studied the effect of antibiotics on Clostridium difficile infection and recurrence 
(Khanna and Pardi, 2016). They plead for antibiotic stewardship to protect native 
microbiota and to prevent infection recurrence. 
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9 Effects of/on therapeutic products 
 
Gut microbiota may inactivate therapeutic drugs rendering them less effective. 
Alternatively, drugs may be biotransformed into active or even toxic derivatives. 
Composition of microbiome may also affect vaccine efficacy. 
Gut microbiota may inactivate therapeutic drugs rendering them less effective. 
Alternatively, drugs may be biotransformed into active or even toxic derivatives (Daliri et 
al., 2017). Xenobiotics1 are detoxified through the host and microbiota metabolism (Li et 
al., 2016). In a first step, oxidation, reduction, hydroxylation reactions are to facilitate 
the excretion of foreign compounds in urine by increasing the polarity. The next step is 
the conjugation reaction (glucuronidation and sulfonation), where they are conjugated 
with endogenous metabolites, again to increase their urinary excretion.  
Microbiota interferes either directly producing enzymes or by altering the capacity of 
drug-metabolizing enzymes or expression of genes. Besides modulating the oral drug 
bioavailability, gut microbiota may also increase drug efficacy (e.g. antitumor 
chemotherapy) or inactivate them (Jourova et al., 2016; Li et al., 2016). The personal 
composition or function of gut microbiota may explain the individually different responses 
towards drug therapy. 
 
Figure 10. Intestinal homeostasis, dysbiosis and oral vaccine effectiveness (GALT: gut-associated 
lymphoid tissue)  
(©Valdez et al./CellPress, Source: Valdez et al., 2014) 
The composition of microbiome may also affect vaccine efficacy (Valdez et al., 2014). 
Dysbiosis results in villous blunting, increased intestinal permeability, and chronic 
                                           
1 a chemical compound foreign to a given biological system. With respect to animals and humans, xenobiotics 
include drugs, drug metabolites, dietary and environmental compounds such as pollutants that are not 
produced by the body. 
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inflammation (Figure 10). Immune cells in the gut-associated lymphoid tissue (GALT) 
respond by creating dendritic cell-mediated T cells and antibody responses to invading 
microbiota. Because the immune system is preoccupied with preventing a systemic 
microbial breach of the intestine, the immune response to a vaccine decreases. 
Dysbiosis may result from e.g. poor hygienic living conditions and poor nutritional status. 
The effect of administering probiotics is varying, probably depending on probiotic strain, 
dose and type of vaccine. Nevertheless, probiotics may have adjuvant effects and act in 
modulating tissue homeostasis. Prebiotics fail to show a positive effect on vaccine 
effectiveness in humans. Studies also suggest that a more diverse intestinal microbiota 
fosters a more protective immune response to oral vaccines against intestinal pathogens 
(Valdez et al., 2014). 
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10 Effects of host genome and life stages 
 
The effect of the host genome on and heritability of the microbiome diversity is rather 
limited.  
The gut microbiota is established as of early life (maternal effect before birth). During the 
first 2-3 years of life there are significant changes as a result of nutrition and overall 
environment. 
With aging, both the physiological modification of human organs and systems as well as 
changes in lifestyle have an effect on the gut microbiota and its interaction with the host. 
10.1 Host genome 
Comparing groups of monozygotic and dizygotic twins the influence of the shared 
environment can be distinguished from the effects of shared genetics (Abdul-Aziz et al., 
2016; Kurilshikov et al., 2017). The phyla Firmicutes, Actinobacteria, Tenericutes, and 
Euryarchaeota were shown to be more heritable, while the highly abundant Bacteroidetes 
phylum shows very little heritability.  
Heritability is also found in microbial gene type groups, including branched-chain amino 
acid biosynthesis and sulphur reduction pathways. But microbial quantitative trait 
mapping in genome-wide association studies reveals that the effect size of host genetics 
on the microbiome is rather modest: it may explain about 10% of microbiome variance. 
Several associations are found between the microbiome and genes associated with the 
host’s innate immunity: pattern recognition receptors sense microorganisms in the 
intestines and therefore modulate microbiome composition and microbiome-associated 
disease. The strongest association is with the C-type lectin receptors with diet, vitamin D 
receptors, and metabolism. Host genetic background through bacteria attachment sites 
exert an important role for the first colonizing bacteria (pioneer flora) (Iebba et al., 
2016). Pioneer flora in turn modulates host genes expression, influencing the successive 
microbial flora. 
10.2 Early life 
Already before birth, the unborn child comes into contact with microorganisms and the 
gut microbiota is established. Also, the mode of birth, vaginal versus caesarean section, 
has an effect on the baby’s initial microbiota. During the first 2-3 years of life there are 
significant changes as a result of nutrition and overall environment. After that, the 
composition of the microbiota stabilises. Microbial colonisation runs in parallel with 
immune system maturation. Disruptions during this complex process of microbial 
colonisation have been shown to predispose to diseases later in life. 
With pregnancy endocrine, metabolic, and immune changes occur that have an effect on 
the microbiota at different body sites of the mother (Nuriel-Ohayon et al., 2016). Even 
though the effects are probably bidirectional as seen above. The abundance of species of 
the Actinobacteria and Proteobacteria phyla in the gut gradually increases, while the level 
of Faecalibacterium, a butyrate-producing bacterium with anti-inflammatory activities 
decreases, as well as individual species richness. This coincides with weight gain, insulin 
insensitivity, and higher levels of faecal cytokines, reflecting inflammation, especially in 
the third trimester of pregnancy.  
Through microbial exposure (probiotics and/or external) there is an early maternal effect 
on the offspring’s microbiota. In a mouse study, maternal microbiota was shown to shape 
the offspring’s immune system in order to respond appropriately to pathogens and 
commensals after birth. After delivery, it is not clear how long it takes for the mother to 
return to baseline microbial populations, if ever. 
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Figure 11. Factors influencing the microbiota of the intestines in humans throughout live. 
(© Rodriguez/ Microb Ecol Health Dis, Source: Rodriguez et al., 2015) 
The human vaginal microbiota is a key component in the defence system against 
microbial and viral infections. Especially the Lactobacillus genus bacteria can create a 
barrier against invaders by maintaining a low pH (< 4.5) and secreting inhibiting 
metabolites. During pregnancy, the level of Lactobacillus increases. 
A normal healthy placenta contains bacteria, although at low levels, with a composition 
more resembling the oral microbiome (Kashtanova et al., 2016; Nuriel-Ohayon et al., 
2016; Rodriguez et al., 2015). The major phylum is Proteobacteria. Also, in the amniotic 
fluid and umbilical cord blood microbes are present. Colonisation of the foetus’ gut begins 
prior its birth as shown from the infant meconium. Meconium bacterial populations are 
dominated by Firmicutes including Enterococcus, Escherichia, Leuconostoc, Lactococcus, 
Lactobacillus and Streptococcus. The potential mechanisms by which bacteria pass from 
the mother to the foetus are still unknown. 
The mode of delivery is determinant (Castanys-Munoz et al., 2016; Kashtanova et al., 
2016; Nuriel-Ohayon et al., 2016; Rodriguez et al., 2015; Rutayisire et al., 2016). 
Infants delivered by caesarean section have lower total gut microbiota diversity in the 
first weeks of life compared with vaginally delivered. The gut of vaginally born infants is 
characterised by bacteria from the maternal vagina, i.e. enriched in the Prevotella, 
Sneathia, Bifidobacterium and Lactobacillus genera, and also includes bacteria present in 
the maternal gut (e.g. Enterobacteriaceae). Children born via caesarean section carry a 
gut microbiota resembling the maternal skin and oral microbiota dominated by 
Propionibacterium, Corynebacterium, and Streptococcus. They have lower counts of 
Bifidobacterium spp. and Bacteroides fragilis but increased numbers of Clostridium 
difficile. Colonisation by the phylum Bacteroidetes is delayed. The mode of delivery may 
also have an effect on the maturation of the immune system, with caesarean section 
potentially leading to immune disorders. Studies have found a higher risk for developing 
asthma, obesity, celiac disease, and type 1 diabetes in children born via caesarean 
section compared with vaginally delivered (Rutayisire et al., 2016). At the age of 6 
months the differences in microbial composition start disappearing. 
Gestational age also influences the establishment. Preterm infants show higher amounts 
of facultative anaerobes belonging to Enterobacteriaceae, and potentially pathogenic 
species such as Clostridium difficile or Klebsiella pneumoniae, and low levels of 
Bifidobacterium and Bacteroides. Term babies had higher genus diversity with genera 
such as Bifidobacterium, Lactobacillus and Streptococcus. 
Breastmilk vs. formula feeding and later solid foods all have their impact on microbiota 
composition next to exposure to several microorganisms from the environment and 
family members. The microbiome matures during the first year of life. Individual species 
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diversity increases and diversity between individuals decreases with age. Human milk not 
only contains bacteria, mainly including streptococci and staphylococci, but is the 
predominant source for establishing a “healthy microbiome” in the new-born. The most 
dominant bacteria in the colostrum included Weisella, Leuconostoc, Staphylococcus, 
Streptococcus, and Lactococcus. The composition later on changes over the course of the 
lactation period. In breast-fed infant intestines Bifidobacteria are the most abundant 
species. The gut microbiota of formula-fed infants is dominated by Enterococci and 
Clostridia. Bifidobacterium can digest the complex oligosaccharides in breast milk, that 
cannot be digested by the infant itself. These oligosaccharides (natural prebiotics) 
selectively promote the growth of beneficial bacteria while inhibiting the growth of 
pathogens. Nowadays, the addition of prebiotics such as GOSs and FOSs to formulas has 
contributed to bringing the microbiota of formula-fed infants closer to that of breast-fed 
infants. The more structurally complex human milk oligosaccharides are not yet present 
in formula. After weening the gut microbial composition changes to species adapted to 
digestion of solid foods such as butyrate producers, including Bacteroides and certain 
Clostridium species. The number of Bifidobacterium, Lactobacillus, and 
Enterobacteriaceae decreases.  
In new-borns the composition of human microbiota progresses from microbes that can 
metabolise the components of breast milk during the lactation period, to microorganisms 
that can utilise components of a solid diet (Rampelli et al., 2016). Next the composition 
becomes gradually more diverse reaching a maximum between 3 and 5 years of age. 
During this maturation stage, there are shared functional stages over time regardless of 
the population or geography. From then on, the composition of the human gut microbiota 
is rather stable throughout life at the phylum level and in overall function (Yatsunenko et 
al., 2012), although differences in composition between individuals may be large. Short-
term dietary interventions do not strongly change the microbiota composition. 
Nevertheless, gene expression and therefore the functional profiles seem to adapt to 
changes in diet rapidly (Graf et al., 2015). 
Coyte et al. tried to understand the mechanisms for maintaining stability (Coyte et al., 
2015). They applied concepts and tools from community ecology to gut microbiome 
assembly. The conclusion was that a high diversity of species is likely to coexist stably 
when the system is dominated by competitive, rather than cooperative, interactions. 
10.3 Aging 
In studying the microbiota of elderly people, one has to distinguish the effects of the 
aging process itself, i.e. the physiological modification of human organs and systems, 
from those of changes in lifestyle. Both have an effect on the gut microbiota and its 
interaction with the host (Mello et al., 2016; Salazar et al., 2017). Next to alterations in 
diet (less vegetables and fruit), lifestyle (decreased mobility), digestive physiology and 
immune function, also frequent multi-drug therapy (including antibiotics) has influence. 
In elderly people a great proportion of phylum Bacteroidetes and a lower proportion of 
phylum Firmicutes with respect to that of younger adults are found. The metabolic 
consequences are that less SCFAs are produced while proteolytic functions are enhanced. 
In turn, they increase the inflammation status of aging people as well as age-associated 
diseases and mental disorders (via communication by the vagus nerve and other 
pathways). 
Some probiotic strains have positive effects by reducing the inflammatory status and 
reduction of influenza infections. They may also reduce the incidence of antibiotic-
associated diarrhoea and Clostridium difficile -associated diarrhoea. 
Experiments with African turquoise killifish (Nothobranchius furzeri) showed that 
replacing the gut microbiota of middle-aged fish by the microbiota of young fish, 
extended the life span and delayed behavioural decline (Smith et al., 2017). In this way 
the aging-related decrease in species diversity was prevented. Young fish receiving 
middle-aged fish microbiota had no effect on life span. 
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Claesson et al. studied the influence of residence location in the community, day-
hospital, rehabilitation or in long-term residential care and therefore diet on gut 
microbiota (Claesson et al., 2012). Persons in long-stay care had a significantly less 
diverse microbiota than community dwellers. 
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11 Effects of environmental factors 
 
The influence of geographic location can be linked with differences in dietary patterns and 
lifestyle in a specific area. 
Co-habitation creates microbial homogeneity. 
The microbiome may interact with environmental chemicals and pollutants in different 
ways.  
As exposures to environmental chemicals induce microbiota alterations that modulate 
adverse health effects, screening environmental chemicals should include toxicity end-
points for the microbiome. 
11.1 Geography 
The influence of geographic location can be linked with differences in dietary patterns and 
lifestyle in a specific area (city, countryside, country, religion, etc.). 
Comparing microbiota composition of volunteers (0-70 years of age) from Venezuela, 
Malawi, and the United States revealed that irrespective of age, the microbiota 
composition clustered according to country (Yatsunenko et al., 2012). The least microbial 
diversity in this study was observed for adult Americans with the genus Prevotella 
underrepresented. When comparing African with European children, De Filippo et al. 
observed increased amounts of Prevotella in African children (De Filippo et al., 2010). 
Faecal microbiota of the African children was rich in Actinobacteria and Bacteroidetes but 
had lower levels of Firmicutes. Conversely, European children were rich in Proteobacteria 
and had over twice the relative abundance of Firmicutes to Bacteroidetes. Likewise, Ou 
and colleagues saw enrichment in Prevotella in Africans compared with African Americans 
(Ou et al., 2013). Similar observations were done in the Tanzanian Hadza hunter-
gatherers compared with Italians (Schnorr et al., 2014). In several African populations in 
these studies an enrichment has been reported in Succinivibrio and Treponema, bacteria 
that have a high-fibre-degrading potential. These characteristic features are consistent 
with a heavily plant-based diet. Also, the Hadza gut microbial ecosystem is depleted in 
Bifidobacterium. This is assumed to be the result of the lack of dairy consumption and 
contact with livestock. 
11.2 Industrialised environment and cities 
The Western lifestyle not only includes a typical diet and lack of exercise that influences 
the gut microbiota, also the physical environment is important (Broussard and Devkota, 
2016). Because humans in the industrialised world spent most of their time indoors, 
microorganisms are exchanged between them and other individuals and the microbial 
environment. Co-habitation creates microbial homogeneity. 
People engaged in shift-work or having a jetlag experience circadian misalignment 
(Broussard and Devkota, 2016). Gut microbiota shows diurnal oscillations, driven 
primarily by the rhythms of food intake, leading to rhythmic composition and functional 
profiles of intestinal bacteria. Circadian misalignment disturbs that rhythm altering the 
gut microbiome in a way that promotes increased energy absorption and positive energy 
balance. 
11.3 Pollution 
Environmental chemicals and intestinal microorganisms might interact in different ways 
(Claus et al., 2016; National Academies of Sciences Engineering and Medicine, 2017):  
● Gut microorganisms themselves can metabolise a variety of environmental 
chemicals;  
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● Microbiota can metabolise environmental chemicals after their conjugation by the 
liver;  
● Environmental chemicals can interfere with the composition of the intestinal 
microbiota; 
● Environmental chemicals can interfere with metabolic activity of the microbiota, 
with potentially deleterious consequences for the host; 
● Microbiota can regulate host genes involved in chemical metabolism. 
Ingested chemicals may pass the gastrointestinal tract until the distal small intestine and 
caecum where they may be neutralised by the microbiota or alternatively converted to 
harmful molecules. An example of the first is 2-nitrofluorene, of the latter, some other 
polycyclic aromatic hydrocarbons that can be transformed into substances with 
oestrogenic properties. Another example: the herbicide propachlor is first absorbed and 
converted by the liver in glutathione, and cysteine conjugates and then deconjugated by 
the intestinal microbes into toxic compounds. Pollutants such as heavy metals and some 
pesticides may be toxic to some microorganisms and in this way dysbiosis may be 
caused. The altered composition and activity of the gut microbiota interfere with the 
intestinal epithelial-barrier function.  
Nevertheless, there is also a reason to look cautiously at these results. e.g. some studies 
suggest that artificial sweeteners such as aspartame, sucralose and saccharin induce 
dysbiosis in animals and humans and that this dysbiosis is responsible for deleterious 
metabolic effects in the host. These studies have been criticised for conclusions not 
supported by data, small sample sizes, non-representative sample, lack of control group, 
lack of baseline data, limited testing episodes and recall bias. 
Mycotoxins produced by filamentous fungi can damage intestinal tight junction proteins, 
cytokine synthesis and viability of epithelial cells leading to increased intestinal 
permeability and degradation of the intestinal mucosal barrier (Du et al., 2017). This 
influences digestion, absorption, metabolism and transport of the nutrients. Mycotoxins 
can exhibit antimicrobial properties modulating the composition of the gut microbiome. 
Also, the microbial activity can be disturbed via modulation of intestinal mucus. Beneficial 
Candidatus savagella and Lactobacillus levels are reduced. The segmented filamentous 
bacterium Candidatus savagella is involved in host gut-associated immune systems. 
Some strains of lactic acid bacteria Lactobacillus and Propionibacterium can effectively 
eliminate potent mycotoxins in the intestinal lumen. 
The role of the human microbiome in modulating absorption, distribution, metabolism 
(activation or inactivation), and elimination (ADME) of environmental chemicals should be 
further studied. As exposures can induce microbiota alterations that modulate adverse 
health effects, screening environmental chemicals should also include toxicity end-points 
for the microbiome (National Academies of Sciences Engineering and Medicine, 2017). 
The research strategy should focus broadly on the three general topics: the effects of 
environmental chemicals on the human microbiome, the role of the human microbiome in 
modulating environmental-chemical exposure, and the importance of variation in the 
human microbiome in modulating chemical–microbiome interactions. This individual-
specific microbiome composition will result in an individual-specific response to 
chemicals.  
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12 Manipulation of the gut microbiome 
 
Modulation of either the composition or the immune-metabolic activity of the gut 
microbiota has been tested to restore health from a diseased microbiome. 
Therapeutic options include a change of diet, addition of non-digestible prebiotics, 
probiotics, and synbiotics, antibiotics and/or faecal microbiota transplantation. 
While some treatments seem effective, most authors ask for studies with larger sample 
sizes (adequate statistical power), homogeneous patient groups, standardised 
treatments, elimination of confounding factors, inclusion of measurements of biomarkers 
related to the immune system and intestinal health, etc. to be able to compare results 
and understand the underlying phenomena. 
Faecal microbiota transplantation enhances microbial diversity, but strict criteria must be 
implemented to ensure quality and prevent risks (e.g. of transferring pathogens and 
disease phenotypes). 
12.1 Diet 
Eating habits, and therefore dietary components, are the main significant determinants of 
the microbial composition of the gut, influencing both microbial populations and their 
metabolic activities, as explained above. Dietary intervention trials to examine the effect 
on diseases share some limitations (Matijasic et al., 2016): the lack of a placebo control 
group, the lack of accuracy in information on dietary intake, complex interactions 
between the consumed food components, individual differences in food metabolism. 
Moreover, short-term interventions are not able to drastically change the microbiota. A 
long-term change in dietary habits might be needed. 
12.2 Prebiotics 
The use of prebiotics or probiotics have variable success in treating diseases. They 
certainly are not one-fits-all. Clinical trials show large differences in response to 
treatment, depending on the disease and the type and amount of prebiotics or probiotics. 
Prebiotics have been shown to be beneficial in the treatment of colorectal cancer in some 
studies (Serban, 2014). Inulin and oligofructose reduced the severity of the disease in 
rats. The best results have been obtained with a combination of probiotic bacteria and 
inulin-oligofructose in both animal and human studies for reducing and preventing 
colorectal cancer. They act via the production of SCFAs and upregulating apoptosis, and 
enhancement of the host’s immune response. However, studies are heterogenic and 
outcomes are varying. 
Oligofructose was shown to be advantageous in the treatment of recurrent Clostridium 
difficile infection (Patel and DuPont, 2015). Prebiotic lactulose showed a trend toward 
clinical benefit in ulcerative colitis (Ghouri et al., 2014).  
A systemic review on the use of dietary fibre (e.g., germinated barley, inulin, 
oligosaccharide/inulin, and psyllium, and high-fibre diet) revealed that only weak 
evidence for improvement is given for UC and pouchitis (Wedlake et al., 2014). For CD 
no positive result was reported. Positive effects of fibre are attributed to its fermentation 
products, SCFAs, in particular, butyrate. 
12.3 Probiotics 
Various inflammatory and metabolic disorders described above are characterised by 
dysbiosis, i.e. disruption of the interactions between microbes and the host. Probiotics 
are proposed to re-establish gut homeostasis and promote gut health. Specific bacterial 
species originally derived from fermented food (dairy products in particular such as 
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yoghurt and kefir, but also sauerkraut, cabbage kimchee and soy bean based miso and 
natto), have beneficial activities.  
The probiotic bacteria act by producing SCFAs (lowering of intestinal pH), by 
metabolising carcinogenic substances, by synthesising vitamins such as B and K, by 
stimulating the immune response either directly increasing the activity of macrophages 
or natural killer cells and modulating the secretion of immunoglobulins or cytokines, or 
indirectly enforcing the gut epithelial barrier (modulating the expression of tight junction 
proteins) and altering the mucus secretion (increasing the expression of mucins), by 
competing with pathogenic and opportunistic microbes and suppressing their growth 
(producing bacteriocins) (La Fata et al., 2017; Raman et al., 2013). 
Health benefits from probiotic supplementation are regarded as being strain specific. 
Strains may be beneficial on their own or in combination. The most common strains 
belong to the species Lactobacillus sp. and Bifidobacterium sp.. A successful combination 
in studies is VSL#3 (Lactobacillus plantarum, L. delbrueckii subsp. bulgaricus, L. casei, L. 
acidophilus, Bifidobacterium breve, B. longum, B. infantis, and Streptococcus salivarius 
subsp. thermophilus (Mimura et al., 2004)). 
Current criteria to qualify for a probiotic are (Grant and Baker, 2016): 
● ability to survive during processing, transport and storage, 
● ability to survive gastric transport, 
● ability to adhere to and colonise the gastrointestinal tract, 
● ability to compete pathogenic bacteria, 
● demonstration of clinical health outcomes. 
Probiotics may be employed for prevention and treatment of colorectal cancer (Ambalam 
et al., 2016; Raman et al., 2013). A few human studies support their beneficial effect. 
Potential modes of action are: mutagen binding, degradation and mutagenesis inhibition, 
prevention of non-toxic pro-carcinogen conversion to carcinogens, lowering of intestinal 
pH by SCFA production, secretion of anti-inflammatory molecules enhancing the innate 
immune response.  
In a systematic review on the role of probiotics in induction or maintenance of remission 
in CD, none of the studies provided conclusive evidence of a beneficial effect (Ghouri et 
al., 2014). Though, in the ulcerative colitis studies various agents showed a trend toward 
improved rates in both induction of remission and maintenance. 
It has been suggested to prevent and combat infections with probiotics (Wolvers et al., 
2010). For infectious diarrhoea in infants and traveller’s diarrhoea, antibiotic-associated 
diarrhoea some evidence exists of positive effects in certain conditions with certain 
strains (e.g. Saccharomyces boulardii, Lactobacillus rhamnosus GG, Lactobacillus casei 
DN 114 001). Results for Helicobacter pylori infection are not conclusive. 
A systematic review on clinical trials discussed the effect of probiotics on constipation 
(Miller et al., 2016). Short-term supplementation of probiotics, mostly yoghurt or other 
forms of fermented milk, in constipated subjects statistically decreased intestinal transit 
time in comparison to the placebo. This effect was not seen in healthy adults. Single-
strain probiotics were more efficacious than multiple strain probiotics. Another systematic 
review selected clinical trials with children (Huang and Hu, 2017). Constipation was 
significantly reduced using probiotics from the Lactobacillus and Bifidobacterium genera, 
but also Streptococcus thermophilus. 
In a study to verify prevention of gestational diabetes mellitus, different treatments 
during pregnancy were compared: a combination of administration of probiotics and 
dietary intervention, a placebo and dietary intervention, and, dietary intervention alone 
(Barrett et al., 2014). This study shows a lower rate of gestational diabetes mellitus in 
the probiotics group. 
 44 
Villanueva-Millan et al. mentioned the use of probiotics in animal studies to treat obesity 
(Villanueva-Millan et al., 2015). Mimura et al. noted a positive effect in treating recurrent 
or refractory pouchitis (Mimura et al., 2004). 
Petrof and colleagues reported on a systematic review on the effect of probiotics on 
critically ill patients (Petrof et al., 2012). Data on ventilator-associated pneumonia show 
a rate reduction with probiotics. The analysed clinical trials did not show a reduction in 
antibiotic-associated diarrhoea and Clostridium difficile infections. The heterogeneity of 
the trials reported outcomes that prevent clear conclusions. 
Microbiota regulate gene expression in specific tissues. A systematic review on probiotic-
mediated modulation of gene expression associated with the immune system and 
inflammation was performed trying to understand the underlying mechanisms (Plaza-
Diaz et al., 2014). Certain strains of Bifidobacterium, Lactobacillus, Escherichia coli, 
Propionibacterium, Bacillus and Saccharomyces induce an anti-inflammatory response: 
downregulation of pro-inflammatory genes, e.g. producing certain chemokines and 
cytokines, and upregulation of anti-inflammatory genes, such as mucin genes and Toll-
like receptors, in enterocytes, dendritic cells. These findings are from in vitro and animal 
studies. Studies in humans are scarce. 
As the microbiota has an effect on the brain, probiotics are proposed as a therapeutic 
alternative to reduce mood disorders such as stress, anxiety and depression. A meta-
analysis performed in 2016 showed that supplementation with probiotics, mostly 
including lactobacilli and bifidobacteria but also Lactococcus and Streptococcus, resulted 
in a statistically significant improvement in psychological symptoms of depression, 
anxiety, and perceived stress in otherwise healthy volunteers (McKean et al., 2017). The 
mode of action might be the competitive exclusion of harmful pathogens, the decrease in 
pro-inflammatory cytokines and the communication with the brain through the vagus 
nerve, leading to changes in neurotransmitter levels or function (Grant and Baker, 2016). 
Most authors ask for studies with larger sample sizes (adequate statistical power), 
homogeneous patient groups, standardised treatments, elimination of confounding 
factors, inclusion of measurements of biomarkers related to the immune system and 
intestinal health, to be able to compare results and understand the underlying 
phenomena. 
12.4 Antibiotics 
Antibiotics are not only beneficial in treating infectious diseases but are also potentially 
harmful agents. Antibiotics are able to shift the gut microbiota (Ferrer et al., 2017; Ianiro 
et al., 2016; Langdon et al., 2016; Lange et al., 2016). This post-antibiotic dysbiosis is in 
general characterised by a loss of diversity both in luminal and mucosal bacteria species, 
a loss of certain important taxa, shifts in metabolic capacity, and by reduced colonisation 
resistance against invading pathogens. Especially in early live this has long lasting effects 
with impaired immune system maturation.  
Dysbiosis might lead to metabolic, immunological, and developmental disorders, and the 
use of antibiotics may have an effect on the prevalence and course of disease. The main 
immediate consequence of antibiotic treatment is the disruption of the ecosystem 
balance, leading to antibiotic-associated diarrhoea. Both opportunistic and exogenous 
pathogens benefit from the dysbiosis status (Iebba et al., 2016). The rise of Clostridium 
difficile infections after antibiotic treatment especially in the elderly is a striking example 
(Ianiro et al., 2016). The impact of antibiotics is dictated by both the type of the 
antibiotic, pharmacokinetics, pharmacodynamics and range of action, dosage, duration 
and administration route as well as by host-related factors including age, lifestyle and 
microbiota composition (Ianiro et al., 2016). 
Nevertheless, antibiotics may be used in treating non-infectious diseases. Again, results 
are varying depending on disease, type of antibiotic and individual patients. IBD (UC and 
CD) potentially can benefit from antibiotic treatment as these diseases are characterised 
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by high prevalence of harmful bacterial genera (Matijasic et al., 2016). Not enough trials 
have been performed and results are controversial. Thus, on one hand exposure to 
antibiotics appears to increase the likelihood of diagnosing CD (but not UC), and 
antibiotic treatment in IBD appears to be associated with more severe disease course, 
there might be on the other hand a beneficial effect of some antibiotics in certain 
treatment regimens (Ianiro et al., 2016; Lange et al., 2016). Likewise, antibiotics may be 
a risk factor in the development of IBS, but certain antibiotics (e.g. rifaximin) may be 
used in the treatment of this disorder (Ferrer et al., 2017; Ianiro et al., 2016). Rifaximin 
is also successful in treating hepatic encephalopathy. 
12.5 Faecal microbiota transplantation 
Faecal microbiota transplantation is becoming an accepted method for the restoration of 
a disrupted microbiota. A faecal suspension from a healthy donor is prepared and 
introduced in the gastrointestinal tract of a diseased person, either by oral capsules, or 
enemas, or duodenal infusions (nasointestinal tube) or colonoscopy. The treatment is 
successful in treating diseases of the gastrointestinal tract, e.g. due to Clostridium 
difficile infection, and to a lesser extent inflammatory bowel disease and ulcerative colitis 
(Gianotti and Moss, 2017). The mode of administration is of little impact on the efficacy 
of reducing Clostridium difficile. 
A systematic review undertaken in 2013 investigated the efficacy and safety of faecal 
microbiota transplantation therapy (Sha et al., 2014). The authors included clinical trials 
with adults and children. The treatment was found successful in Clostridium difficile 
infection, it improves UC, but is disappointing in CD. Also in children the treatment was 
beneficial and safe. For chronic fatigue syndrome and metabolic syndrome in adults some 
effect was reported. Stool composition after faecal microbiota transplantation showed an 
increase in microbial diversity including anti-inflammatory and/or SCFA-producing 
bacteria. Adverse events were uncommon but transient, and may include flatulence, 
rectal discomfort, diarrhoea, nausea, abdominal cramping, etc. An earlier systematic 
review on the usefulness of faecal microbiota transplantation in patients with Clostridium 
difficile infection came to the same conclusion (Gough et al., 2011). Results depended on 
the type of donor, the preparation of the material, the dosage and patient pre-treatment. 
The exact mechanism of disease remission is not known. It might be due to the change 
in bacterial communities, alterations in host metabolic profiles, or the introduction of 
peptides from the donor that modify host immune responses. (Gianotti and Moss, 2017). 
It is even not known whether Clostridium difficile is effectively eradicated or reverted to a 
sporulating state. 
Faecal microbiota transplantation has also been suggested to remediate neuro-
developmental disorders, autoimmune diseases and allergic diseases (Borody and 
Khoruts, 2011). Preliminary reports exist for Parkinson’s disease, fibromyalgia, chronic 
fatigue syndrome, multiple sclerosis, myoclonus dystonia, obesity, insulin resistance and 
the metabolic syndrome and childhood regressive autism.(Sha et al., 2014).  
 
Faecal microbiota transplantation enhances microbial diversity. Microbiota of treated 
patients has been shown to resemble that of the donor after therapy. The preparation 
should be standardised. It is not known what contact with oxygen might result in. The 
incomplete characterisation of the material delivered into the patient might be a 
drawback and hampers standardisation. Another disadvantage is the risk of transferring 
microbial pathogens, or undesired disease phenotypes, such as obesity, metabolic 
syndrome, and fatty liver, as shown in mouse studies (Hansen and Sartor, 2015). In 
selecting donors, the primary criterion should be the overall donor's health. Medical 
examination, screening test and medical history should not reveal gastrointestinal 
diseases or other diseases correlated with dysbiosis, or infections (e.g. HIV, hepatitis). 
The donor should not have used antibiotics recently (Borody and Khoruts, 2011; Sha et 
al., 2014). 
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Stool banks have been established in some countries, for example, OpenBiome and 
AdvancingBio in the United States, the Taymount Clinic in the United Kingdom, the 
Netherlands Donor Feces Bank (NDFB), and the Chinese FMT bank (Ma et al., 2017). 
With more knowledge becoming available faecal microbiota transplantation may be 
replaced by defined preparations of their constituent therapeutic factors (Langdon et al., 
2016).  
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13 Legal and ethical aspects 
 
Probiotics are subject to a scattered legal framework for food, feed, and health claims.  
Faecal microbiota transplantation is not regulated at the EU level. 
Since the human metagenome (combination of the human genome and the microbiome) 
together encode a person’s physiological and psychological traits, the microbiota may be 
considered to be part of a person’s identity. 
Commercial application raises concerns about property rights, accessibility of data, 
patentability of faecal microbiota profiles, financial benefits, etc. When performed outside 
of the regulated establishment, there are additional concerns on safety, follow-up, and 
exaggerated expectations. 
The delay in appropriate governance hinders further clinical trials and applications and 
therefore prevents adequate therapies to be developed to replace the current, costly 
treatments. 
13.1 Legal analysis 
The World Health Organisation’s definition of probiotics is: “live microorganisms, which, 
when administered in adequate amounts, confer a health benefit on the host” (WHO, 
2006). In EU legislation the notion probiotics does not exist. 
In the EU probiotic microorganisms used as or in foods and food supplements are 
considered as food ingredients and are not subjected to a centralised pre-market safety 
assessment due to traditional and safe use in fermented foods. Food businesses have 
general obligations under the EU Food Hygiene Regulation (EC) No 852/2004 (EU, 
2004) essentially in relation to the compliance with microbiological criteria for foodstuffs. 
However, if new, they need to comply with the EU Novel Food Regulation (EU) 
2015/2283, which lays down rules for novel foods that were not used before 1997 (EU, 
2015).  
Member State regulators, responsible for control of food businesses under the food 
hygiene regulation, often use requirements and guidance documents (e.g. from EFSA) 
developed for feed probiotics as reference. Since these are regulated as feed additives 
(see below), they require a substantial registration dossier prior to the EU authorisation.  
Food Supplements Directive 2002/46/EC lays down specific rules for vitamins and 
minerals used as ingredients of food supplements (EU, 2002). Substances other than 
vitamins and minerals are not directly covered by this directive and rules regulating 
these substances are still governed by individual EU Member States. 
Regulation 609/2013 on dietetic food covers infant formula and follow-on formula, 
processed cereal-based food and baby food, food for special medical purposes, and total 
diet replacement for weight control (EU, 2013a). 
From a marketing point of view, probiotic manufacturers try to label their products with a 
health claim. Health claims are regulated by the Health Claim Regulation (EC) 
1924/2006 (EU, 2006) and its implementing legislation (EU, 2008). The regulation 
deals with beneficial nutritional properties (nutrition claim), the relationship between a 
food/constituent and health (health claim) and food/constituents significantly reducing a 
risk factor in the development of a human disease (reduction of disease risk claim). The 
risk assessment is based on evidence weighing of human studies (but not studies 
designed for the treatment of diseases), efficacy studies in animals and non-efficacy 
studies in humans, animals and/or in vitro. The only approved probiotic claim in the EU is 
generic for yoghurt bacteria: production of lactase and aid in digesting lactose in subjects 
with intolerance (EU, 2012). 
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Claims on probiotics have not been approved in the EU because of:  
● Insufficient characterisation 
● Non-defined claims 
● Non-beneficial claims 
● Not all measurable outcomes reflect a direct benefit for humans 
● Lack of pertinent human studies 
● The quality of studies  
Nutrition and health claims will only be allowed on food labels if they are included in one 
of the EU positive lists (Register for claims: http://ec.europa.eu/nuhclaims/). The use of 
the term probiotic is not permitted under the Health Claim Regulation as of 14 December 
2012 (EU, 2012). The term ‘probiotic is considered an implied health claim. This means 
that products cannot be sold in the EU claiming to be probiotics.  
Food products carrying claims must also comply with the provisions of Nutritional 
Labelling Regulation 1169/2011 on information to consumers (EU, 2011).  
In 2013, the European Commission introduced the Generic Descriptors Regulation 
No. 907/2013 (EU, 2013b), which sets out the rules for applications concerning the use 
of generic descriptors. Generic descriptors are words which have traditionally been used 
to indicate a characteristic of a class of foods or beverages which could imply an effect on 
health such as “digestive”. In the past, these words have been exempt from the ban 
under the Health Claim Regulation. The Generic Descriptors Regulation foresees that 
generic descriptors for food and beverage products, which could be perceived as health 
claims, would only be allowed if they have been in use for the product for more than 20 
years in a Member State. Where a company demonstrates use of these descriptors prior 
to the entry into force of the Generic Descriptors Regulation, then, it would be possible to 
apply for an exemption to the ban.  
Microorganisms to be included in feed or animal drinking water are regulated by the 
Feed Additives Regulation (EC) No 1831/2003 (EU, 2003), if they are intended to 
perform functions such as favourably affecting animal production, performance or 
welfare, particularly by affecting the gastro-intestinal flora or digestibility of 
feedingstuffs, and others. 
When microorganisms are proposed for use in regulated products that require market 
authorisation, EFSA is required to assess their safety. Independently of any particular 
specific notification in the course of an authorisation process, EFSAs Qualified 
Presumption of Safety (QPS) (https://www.efsa.europa.eu/en/topics/topic/qualified-
presumption-safety-qps) provides a generic safety pre-assessment approach of a defined 
taxonomic unit for use within EFSA that covers risks for human, animals and the 
environment. Several microorganisms that are present in the human gut have been 
included in the QPS list (Ricci et al., 2018). 
In the absence of harmonisation—probiotics are subject to national provisions, resulting 
in a fragmented EU market place. At the moment, most EU countries consider the term 
“probiotic” a health claim. 
Faecal microbiota transplantation is not regulated at the EU level, in Australia or China 
(Edelstein et al., 2015). However, the Dutch authorities consider stool samples to be 
drugs. The United States’ FDA considers it as an investigational new drug (IND) meaning 
a long and arduous IND procedure as for medications (FDA, 2013). FDA has waived the 
IND requirement only for treatment of recurrent Clostridium difficile infection, under 
conditions (Ma et al., 2017). In Canada, it is regulated as a new “biologic drug” that can 
only be used in clinical trials.  
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13.2 Ethical considerations 
Due to the close interaction with the human body and the fact that each individual’s 
microbiota is unique, the microbiota may be considered to be part of a person’s identity 
(Metselaar and Widdershoven, 2017; Rhodes, 2016). Both the human genome and the 
microbiome (together the human metagenome) encode a person’s physiological and 
psychological trait. The question arises whether it is therefore also the person’s property. 
For use in research, clinical trials and eventually commercial applications, microbiota 
samples may be compared with other biological samples. Participation in clinical trials 
follows the normal rules. With a person's informed consent the participant explicitly 
agrees with the study goals and potential risks. It is also worthwhile to think about 
participating in research on microbiota and providing material for biobanks for the 
interest of the general public health, as the gathered knowledge would be to the benefit 
of everybody. 
Being part of identity the question rises to what extent faecal microbiota transplantation 
may alter essential characteristics of a person (Metselaar and Widdershoven, 2017). 
Changes to the psychology may alter family relations. Also, an altered microbiota can be 
transmitted through offspring; faecal microbiota transplantation therefore might have 
consequences to the next generation. The discussion has some similarities with altering 
germline genomics. 
The human gut microbiota is sometimes presented as a “virtual organ” that should be 
treated as human tissue (Ma et al., 2017). Faecal microbiota transplantation is then a 
form of organ transplantation, but simpler to perform than other organ transplants, 
without the need for immunological matching of donor and recipient or the need for 
immunosuppression following the procedure (Borody and Khoruts, 2011). However, 
extensive screening of donors needs to be performed in order not to transfer pathogens 
or the risk for other diseases that might be associated with the gut microbiota, as 
discussed before. The influence of other factors such as gender, age, pregnancy, religious 
background (diet) is still uncertain (Ma et al., 2017).  
For the donor the necessary guarantees must be in place to ensure privacy and 
confidentiality. At the same time, it must be clear for donor and medical staff how 
unsolicited and secondary findings should be handled. As a person’s microbiota is unique, 
it may become possible to identify an individual analysing its faeces (its microbial 
fingerprint that also contains human DNA). Microbiota can reveal a person’s lifestyle, 
travelling history, etc. 
Potential patients are extra vulnerable as faecal microbiota transplantation is often the 
last resort when other treatments fail (Ma et al., 2017)., It is challenging to obtain an 
informed consent of the patient in an area where knowledge on the treatment is still 
limited especially regarding possible side effects on mood and behaviour. Faecal 
microbiota transplantation has until now only been proven effective in treating 
Clostridium difficile infection. Patients might be tempted to consent without fully 
understanding the risks of new or still to be verified therapies. 
Commercial application raises concerns about property rights, accessibility of data, 
patentability of faecal microbiota profiles, and financial benefits (Ma et al., 2017). 
Commercial faecal microbiota transplantation circumventing the guidance of the hospital 
and health care professionals (DIY kits) may introduce issues as with the reproduction 
industry: safety, follow-up, exaggerated expectations, etc. 
Faecal microbiota transplantation therapy may induce reactions of disgust toward the 
object of faeces, fear of transmission of potential pathogens and feelings of violation and 
degradation of human dignity (Ma et al., 2017). 
The delay in appropriate governance hinders further clinical trials and applications and 
therefore prevent adequate therapies to be developed to replace the current, costly 
treatments. 
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14 Discussion/Conclusion 
 
Research on human gut microbiota has made great progress in the last decade. Various 
techniques make it possible to identify its composition concerning organisms, genes, 
proteins and functions. Nevertheless, what really constitutes a “healthy” gut microbiota 
remains still unclear. The biodiversity between different healthy individuals is even 
greater than expected. There is consensus that the healthy adult gut is dominated by 
Firmicutes, Bacteroidetes, Actinobacteria, and Verrucomicrobia (Human Microbiome 
Project Consortium, 2012). Within these phyla, there is still large inter-individual (and 
intra-individual) variability, with each person harbouring a unique microbiota profile. 
Species are shared within families and communities. Despite the differences on the 
species level, the functions carried out by these species appear to be similar in every 
person’s gastrointestinal tract (Marchesi et al., 2016). 
It must be stressed that to date research on gut microbiota is very bacteria-centric. Very 
few studies have looked at the viral component (or virome) and eukaryotes such as 
protozoa, yeast and fungi or even bacteriophages.  
The microorganisms in the gut not only assist in the digestion of food, but they are also, 
perhaps more importantly, involved in establishing the immune system response, the 
defence against pathogens, the endocrine system and even mental health. Already 
before birth they are present and influence human health. 
The composition is determined by and varies greatly according to the diet, but also 
lifestyle, age, genetics, disease, antibiotic use, etc. are important (Figure 12). Dietary 
changes can account for up to 57% of gut microbiota changes, whereas genes account 
for no more than 12% (Clark and Mach, 2016). 
 
Figure 12. Factors, which influence the composition of the human gut microbiota, with special focus 
on diet. 
(© Graf/ Microb Ecol Health Dis, Source: Graf et al., 2015) 
Diet can modify the intestinal microbiome, which in turn has a profound impact on overall 
health. A load of evidence exists for the link between dysbiosis, the disturbed balance in 
the microbiota composition, and disease. However, not always a causal relation is 
established. We still lack much in terms of mechanistic insight into how microbes 
contribute to the onset of disease. Many animal studies have been conducted, while 
limited data is available concerning human studies. A major difficulty is the variation in 
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the normal functional human microbiome, but also the use of different techniques to 
assess dysbiosis in humans which might lead to the generation of different results (Leung 
et al., 2016). 
Not only diseases related to the gastrointestinal tract (IBD, Clostridium difficile infection, 
coeliac disease, liver diseases) are correlated with the microbiota, but also diseases like 
cardiovascular diseases, autoimmune diseases and mental disorders like depression, 
Alzheimer’s disease are affected. 
Considering the relationship between microbiota and disease, and the fact that diet has a 
dramatic effect on its composition, many attempts have been made to cure diseases 
using prebiotics, probiotics or synbiotics. Trials have varying success.  
Interfering by changing the diet or supplements may have effect, but the results in 
individual cases are highly influenced by the initial composition of an individual’s 
microbiota (Flint et al., 2012). Clinical trials prebiotics, probiotics or synbiotics are hard 
to compare due to confounding factors. Treatment with antibiotics has also been 
suggested. Faecal microbiota transplantation therapy is clearly beneficial in curing 
Clostridium difficile infections, but more research needs to be performed for other 
diseases. 
Existing legislation in relation to probiotics does not facilitate their use in preventing and 
curing diseases. Furthermore, the legal description of faecal microbiota transplantation is 
balancing between the notion “drug” and “biologic”. Ethical issues are especially 
important concerning faecal microbiota transplantation therapy. 
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15 Examples of national and international initiatives 
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16 Methodology of this study 
 
The study is focussed on the human gut microbiome. As a consequence information on 
microbiomes from other organisms (e.g. animals) or other human compartments (e.g. 
skin) are not covered.  
This report is based on literature searches performed on the Web of Science and PubMed 
databases in Fall 2017. The search string that was used, is: 
(Microbiome OR Microbiota)  
AND 
Influenc* 
AND 
(Nutrition* OR Nutrient* OR Probiotic* OR Environment* OR Pollution OR Infect* 
OR Health OR Well*being OR Disease OR Obesity OR Cancer OR Aging OR 
Therapeutic* OR ADME OR Pharma* OR Toxic*) 
Only articles that focussed on the gut microbiota were retained. The search was limited 
to articles available in English. A total of 5810 articles were left. Manual searches through 
reference lists of the articles were also performed to identify additional studies. Review 
articles were also kept. 
Based on this information, a selection was made in order to cover the range of findings 
and subjects, acknowledging that it was not the purpose of this study to provide a 
detailed analysis of a specific field. The outcome should only be regarded as a top-level 
view of the different directions in which research is conducted and in which areas 
information is still relatively weak and others for which the body of evidence is convincing 
The information was classified and grouped according to the requested topics aiming at 
providing an overall picture. However, these classifications may not be as intended by 
the authors of the original research. Also, some wording may reflect the understanding of 
the authors of this study rather than the claims of the authors of the original 
publications. Nevertheless, the authors of this study have tried to remain unbiased and 
only presenting discussions and/or diverging views as they appear in publications.  
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